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ABSTRACT 
 
 High throughput screening (HTS) is the dominant force in modern drug discovery. 
Through the evaluation of large structure collections, novel drug leads can be rapidly assessed 
for modulation of medicinally-relevant biological targets. This occurs through the interplay of 
three intrinsically linked facets, namely A) the chemical collections being screened, B) the 
biomolecular targets against which the compounds are assayed, and C) the technologies 
employed in the screening process.  
In this multipronged treatment, each of the three above mentioned concepts will be 
explored. Chapter 2 will explore chemoinformatics methods for quantifying structural 
complexity and diversity in large screening libraries. Chapter 3 will describe an optical 
biosensor-based assay for inhibitors of the RNA-protein binding interaction responsible for type 
1 myotonic dystrophy (DM1), a hereditary degenerative disorder. Finally, Chapter 4 will 
explore the limits of small-molecule detection in a novel laser-based optical biosensor 
technology. Taken together, these three stories encompass the full range of HTS concepts and 
offer a glimpse into the future of drug discovery. 
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CHAPTER 1: OPPORTUNITIES FOR THE ADVANCEMENT OF HIGH-
THROUGHPUT SCREENING IN DRUG DISCOVERY 
 
1.1 Background 
High throughput screening (HTS) has become the dominant method for pharmaceutical 
lead discovery. Between 1999 and 2008, 90% of first-in-class FDA-approved small-molecule 
therapeutics were discovered in a screen.1 Developed as a result of advances in robotics, 
miniaturization, signal detection, and combinatorial synthesis, HTS allows for the rapid 
evaluation of massive collections of small molecules in biological assays.2  
HTS is ultimately reliant on three components that are intrinsically linked: 1) chemical 
structures in large screening libraries, 2) biological targets that can be modulated by chemical 
agents, and 3) technologies that permit the detection and measurement of such interactions 
(Figure 1.1). The following chapters will discuss each of these components in depth. 
 
Figure 1.1: Success in high-throughput screening (HTS) is dependent on three interconnected components: diverse 
screening collections, medicinally-relevant biochemical targets, and rapid, sensitive detection technologies. 
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1.2 Chemical Screening Collections 
1.2.1 Background 
The goal of HTS is to identify novel drug leads by assessing the ability of screening 
compounds to modulate biological molecules and processes. Consequently, the composition of 
screening collections directly influences the pharmaceutical leads that are developed as well as 
the types of biological targets that can be modulated. This realization – that quality and not 
necessarily quantity is the key determinant of success in a HTS library – demands a method for 
evaluating the structural makeup of large chemical collections. 
1.2.2 Molecular Properties in Screening Collections 
Historically, natural products have been the mainstay of drug discovery.3 However, it has 
become increasingly clear that a reliance on the discovery of new natural products yields 
diminishing returns,4 and synthetic chemistry has filled the need for new drugs. That being said, 
a recent report5 analyzed the output of synthetic medicinal chemists over the past 50 years and 
observed a trend towards increased sp2 character6 that can be attributed in part to the increased 
use of sp2-sp2 coupling reactions.7 One result of this trend is that many screening collections are 
populated by low molecular weight, relatively planar organic compounds with high sp2 character 
and low, if any, stereochemical complexity.  
1.2.3 Efforts at Populating Screening Libraries with Diverse Structures 
Several approaches have arisen to meet the growing need for complex small molecules 
intended to enrich screening collections. Diversity-oriented synthesis (DOS) is one such 
approach that couples simple starting materials and transforms the resulting intermediates into 
multiple complex structures bearing natural product-like features.8-10 A number of  DOS 
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variations have also been developed such as the synthesis and derivatization of natural product-
inspired scaffolds,11-12 biology-oriented synthesis,13 and the synthesis of chiral and 
conformationally constrained oligomers.14 Additionally, while not specifically designed to 
populate HTS screening libraries, numerous total synthesis efforts have utilized iterative cascade 
reactions,15 biomimetic dimerization of oligomers,16 and collective synthesis17 approaches to 
rapidly access entire classes of natural products and analogues. These collective efforts are 
motivated by the recognition that molecular complexity is intrinsically linked to a compound’s 
origin,18-19 and this may be driving pharmaceutical synthesis back towards molecular properties 
found in natural products. CHAPTER TWO will discuss chemoinformatics methods for 
analyzing large structure collections. These approaches permit the rapid evaluation of screening 
libraries, both to quantify complexity and diversity of existing compounds as well as to direct the 
syntheses of future compounds. This highly successful work represents a new direction for 
synthesis inspired by nature, and it has been reported in a recent publication.20  
 
1.3 Under-Represented Targets in Drug Discovery 
1.3.1 The Protein-Dominated Target Landscape 
As mentioned previously, current screening collections are dominated by compounds of 
high planarity and low stereochemical complexity. Thus, the majority of HTS success stories 
involve biological targets readily modulated by such compounds. For example, protein kinases 
are one of the most successful target classes for HTS since enzymatic activity can be inhibited at 
the ATP binding site by highly aromatic compounds with no stereogenic centers.21 However, 
identification of HTS leads for more complex targets such as protein-protein interactions22 and 
transcription factors23 has proven far more difficult. The disparity in so-called “druggable” 
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targets is shown in Figure 1.2: enzymes and receptor proteins are overwhelmingly represented by 
drugs currently on the market. HTS endeavors in certain therapeutic areas such as antibacterials 
have shown very poor outcomes.24 One reason for this lack of success is that compounds active 
in these areas are often larger and more stereochemically complex than the majority of 
compounds found in screening collections.25 Another reason deals with the accessibility of 
targets not fitting the classical “lock-and-key” model for drug targeting. Accordingly, scientists 
must look beyond the obvious, and seek some higher-hanging fruit. 
 
Figure 1.2: Marketed small-molecule drug targets by biochemical class. The majority of drugs target enzymes or 
receptor proteins. From Hopkins et al.26 
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1.3.2 Targeting RNA Secondary Structure 
As the intermediary between the genome and the proteome, RNA represents a tantalizing 
goal for future drug discovery. Previous research in the Hergenrother group has focused on the 
targeting of secondary structure in RNA, wherein perturbations in a duplex present potential 
binding sites in the form of bulges, hairpin loops, and internal loops.27 Spirocyclic wedge 
structures were shown to be selective binders for RNA bulges,28 and dimers of deoxystreptamine 
were shown to bind RNA hairpin structures with size-selectivity.29-30 In an effort to discover 
small-molecule binders for RNA internal loops, attention was turned to disease states that bore 
such structures as the result of aberrant mutations. 
1.3.3 Triplet Repeat Expansion Disorders 
 A wide area of growing medicinal research surrounds the triplet repeat expansion 
disorders (TREDs).31-32 Spontaneous expansion of DNA triplets can occur from slippage during 
cell division and gamete formation. A normal human genome contains numerous regions of short 
consecutive repeats; however, in TREDs a triplet can be repeated hundreds or thousands of 
times.33 These expansions can occur in both coding and non-coding regions. When the repeat is 
in the open reading frame, a deleterious effect is observed at the protein level; the best-known 
examples are Huntington’s disease and other so-called “polyQ” disorders where the repeat 
expansion is encoded to repeating glutamine residues.34 However, when the expansion is in the 
non-coding region, the result is an aberrant RNA that can itself act as the pathogenic agent. 
Expansions containing high C/G base content can exist as stable, ordered structures capable of 
interacting with other cellular components and consequently having further deleterious effects.35 
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1.3.4 Type 1 Myotonic Dystrophy (DM1) 
 Type 1 myotonic dystrophy (DM1) is a TRED characterized by a (CTG) expansion in the 
3’-untranslated region of the DMPK gene.36 This DNA expansion is transcribed to a poly(CUG) 
RNA that forms a stable ladder of repeating U-U mismatch internal loops.37 Pathogenesis arises 
from poly(CUG) sequestering the protein MBNL1, a pre-mRNA splicing regulator.38-39 The loss 
of MBNL1 activity gives rise to a host of symptoms all resulting from mis-splicing of various 
target pre-mRNAs (Figure 1.3). Accordingly, many research groups have approached this 
disease with the aim of inhibiting the binding interaction between poly(CUG) RNA and MBNL1. 
Shown in Figure 1.4, these have largely involved multimeric strategies involving peptides,40 
functionalized peptoids,41 and antisense morpholino oligomers.42 Small molecule strategies have 
been considerably less common, with one case involving a screen of known RNA binders43 and 
one involving a rational design approach.44 CHAPTER THREE will discuss the development 
of a novel assay for the detection of new binding inhibitors of poly(CUG) RNA and MBNL1. 
This assay, together with the associated screen and validation assays, has broad implications for 
any disease model governed by RNA-protein interactions. 
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Figure 1.3: Mis-splicing of pre-mRNA as symptomatic consequence of triplet repeat expansion in DM1. Aberrant 
expansion of a CTG repeat in the DMPK gene gives rise to a poly-CUG RNA that sequesters MBNL1 protein and 
consequently prevents normal splicing events. From O’Rourke33 and Ranum.45  
 
Figure 1.4: Strategies for targeting type 1 myotonic dystrophy (DM1). A) Peptide-based inhibitors generated 
through combinatorics.40 B) Multimeric peptoids functionalized with nucleic acid binders, with backbone spacing 
conferring selectivity to triplet repeat expansions.41 C) Antisense morpholino-oligomers display sequences 
complementary to (CUG) RNA repeats.42 D) Small-molecule inhibitors discovered by screening43 and design.46 
  
A) B) 
C) D) 
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1.4 Technology in HTS 
1.4.1 Methods for Detecting Biological Processes 
 One main reason for the prevalence of enzymes as drug targets is the relative ease of 
designing HTS assays around enzymatic processes. These assays can take many forms, but they 
often involve a fluorescent or colorimetric readout, are amenable to miniaturization, and are 
compatible with automated robotic screening platforms. Assays are generally classified as being 
target-based (occurring in controlled in vitro settings) or phenotypic (e.g., taking place in cell 
culture), but both approaches have benefits and limitations 
1.4.2 Limitations in Detection and Throughput 
A major concern in any assay is the introduction of false positives. For assays built 
around a fluorescent readout, the inherent fluorescence of screening compounds can present a 
source of error.47 Colorimetric methods can be plagued by aggregation behaviors that cause 
conglomerates of small molecules that in turn can act to disrupt assay signal.48 And a problem in 
labeled systems such as FRET assays can arise from the artifice of conjugating probes and tags 
to the protein being studied. Meanwhile, techniques that rely on cell morphology (e.g., confocal 
microscopy, flow cytometry) can be extremely information-rich but simultaneously hindered in 
terms of throughput. 
1.4.3 Label-free Optical Biosensors 
 A general technology class that can speak to many of the previously mentioned 
limitations is the optical biosensor, which is a detection device with some measurable 
characteristic of light coupled to a change on the sensor surface. The advent of surface plasmon 
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resonance (SPR) brought along an entire field of label-free optical sensors that were no longer 
bound by the readout limitations of previous enzymatic assays.49 These new biosensors come in 
many forms, including SPR, nanohole arrays, ring resonators, and photonic crystals.50-51 The 
photonic crystal biosensors have been extensively explored in the Cunningham group 
(Department of Electrical and Computer Engineering, University of Illinois), applying label-free 
detection methods to cellular and material studies.52-53 In a previous collaborative effort with the 
Hergenrother group, a general assay for detecting inhibitors of DNA-protein binding was 
reported,54 and this work led directly into an analogous effort to detect inhibitors of RNA-protein 
interactions (Chapter 3). In CHAPTER FOUR, the discussion will focus on the latest efforts to 
push the limits of detection even further, to enable the direct measurement of small-molecule 
binding to a protein surface. This work has far-reaching potential for future drug discovery, and 
has been reported in a recent manuscript.55  
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Figure 1.5: The photonic crystal (PC) biosensor.54 A nanofabricated polymer diffraction grating overcoated with 
high refractive index material generates a standing resonance wave upon illumination. The reflected wavelength 
varies according to the amount of biomaterial adsorbed on the sensor surface, permitting label-free biosensing. 
Figure adapted from Heeres et al.50 and Chan et al.54 
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CHAPTER 2: CHEMOINFORMATIC ANALYSES OF STRUCTURAL 
COMPLEXITY AND DIVERSITY IN CHEMICAL LIBRARIES 
 
Portions of the text and figures of this chapter are adapted from the original paper, titled “A Ring 
Distortion Strategy to Construct Stereochemically Complex and Structurally Diverse 
Compounds from Natural Products” (Huigens, R.W.; Morrison, K.C.; Hicklin, R.W.; Flood, T.A; 
Richter, M.F.; Hergenrother, P.J. Nat. Chem. 2013, 5: 195-202) with permission from the 
publisher. Syntheses of all molecules shown were performed by Huigens, Morrison, Hicklin, and 
Richter; all computations and analyses are the original work of the author. 
 
2.1 Complexity-to-Diversity (CtD): Initial Chemoinformatics Efforts 
In an effort to populate screening collections with diverse compounds of high structural 
complexity, a new synthetic platform, called Complexity-to-Diversity (CtD), was developed. 
Taking inspiration from nature,1 which uses complex intermediates to arrive at vastly different 
natural products, the CtD approach uses natural products as starting materials for short synthetic 
routes that achieve diverse scaffolds by a series of ring distortion reactions (Figure 2.1A). This 
method is distinct from previous medicinal chemistry approaches to diversifying natural 
products, which primarily consisted of peripheral transformations to the parent natural product 
that left the core scaffold intact. CtD permits the incorporation of these precedented peripheral 
transforms, but only when combined with skeletal rearrangements. Importantly, every 
intermediate on the path to a final target structure is itself worthy of inclusion in a compound 
collection of complex molecules. The result is the rapid generation of hundreds of compounds 
derived from a few core transformations of a single, readily available natural product. 
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The early stages of this project focused purely on the planning of synthetic routes to 
achieve diverse compounds, which is discussed elsewhere.2 It quickly became apparent, 
however, that the syntheses required a formal evaluation method beyond a mere eye test, which 
is inherently subjective and represents some arbitrary and qualitative notion of how “interesting” 
a compound is. Instead, what was required was a more quantitative means of evaluating the 
otherwise abstract notions of “complexity” and “diversity.” This chapter will outline the various 
chemoinformatics methods explored throughout the development of CtD. The developed 
methods serve to illustrate the success of the CtD approach as a means to populate regions of 
chemical space with compounds displaying specific physicochemical properties that are deficient 
in current screening collections. Furthermore, these methods will point to the future of CtD, 
demonstrating the use of computational tools to direct synthetic efforts. Meanwhile, CtD has the 
potential to be applied to dozens of natural product starting points, and efforts to expand the 
CtD-generated screening collection are ongoing. The discussion here will focus on the first three 
natural products utilized in this synthetic practice. 
2.1.1 CtD Libraries 
 The initial demonstration of the Complexity-to-Diversity (CtD) approach used readily 
available natural products from three distinct compound classes: gibberellic acid (G), a terpene, 
adrenosterone (A), a steroid, and quinine (Q), an alkaloid. The target compounds derived from 
each natural product are shown in Figure 2.1B-D. Each target was realized in ≤5 steps by a series 
of ring distortion reactions with minimal peripheral transformations. The full set of intermediates 
and targets is shown in Figure 2.2 (which together with the parent compounds Q, A, and G, will 
hereafter be referred to as the “CtD52” set). 
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Figure 2.1: The Complexity-to-Diversity (CtD) approach to accessing diverse scaffolds for novel screening 
compounds. A) Representative ring-distortion reactions to generate new skeletal cores. B) Gibberellic acid (G) and 
target compounds G1-G6. C) Adrenosterone (A) and target compounds A1-A5. D) Quinine (Q) and target 
compounds Q1-Q5. Figure from Huigens et al.2  
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Figure 2.2: Complete “CtD52” set, comprising all target and intermediate compounds in the synthetic routes for the 
sets based on gibberellic acid (G), adrenosterone (A), and quinine (Q). Figure from Huigens et al. (supplementary 
information).2  
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2.1.2 Principal Moment of Inertia (PMI) 
2.1.2.1 PMI Concept and Justification 
One of the initial aims of CtD was to produce structures that represented a departure from 
the highly planar compounds found in screening collections derived from combinatorial 
synthesis. Structure shape was therefore a logical starting point for analysis. Initially, shape 
considerations consisted of rendering structures in their lowest-energy 3D conformations and 
comparing them by inspection. However, this merely represented a slightly more sophisticated 
version of the 2D eye test, and was abandoned as being insufficiently quantitative. A graphical 
representation of shape categories was attempted using Principal Moment of Inertia (PMI).3 In 
this method, primary rotational axes (i.e., moments of rotational inertia I1, I2, and I3) are 
calculated from an energy-minimized 3D chemical structure. These axes inform how the 
structure will rotate or tumble in space; by graphing the ratios of calculated PMI values (I1/I3 and 
I2/I3), a given compound will fall somewhere within a bounded region to indicate its gross order 
of dimensionality. That is, a compound can be said to be basically rod-like (linear/1-
dimensional), disc-like (flat/2-dimensional), or sphere-like (globular/3-dimensional). 
Importantly, previous analyses of screening collections have suggested that such compounds are 
largely rod- and disc-like.4 By generating compounds that move away from the left-most (i.e., 
“linear/flat”) region of “PMI space” two goals could potentially be achieved: compounds would 
appear to be distinct from standard screening collections, and structures in the “sphere-like” 
region might represent the three-dimensionality necessary for accessing the active sites of more 
complex biological targets.4  
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2.1.2.2 Shape Analysis of CtD52 Set by PMI 
 The PMI analysis as applied to the CtD52 set is shown in Figure 2.3A. Gibberellic acid 
derivatives are shown as blue diamonds, adrenosterone derivatives are shown as red squares, and 
quinine derivatives are shown as green triangles. These derivative sets are individually 
represented in Figures 2.3B-D, with connected arrows tracing a “synthetic path” that follows the 
changes in shape along the synthetic route to each target structure. Each compound set is spread 
throughout the PMI space, indicating a diversity of non-overlapping shapes. Unsurprisingly, 
there is very little occupation of the lower region representing purely “disc-like” shapes; this is 
reflective of the general non-planarity of the structures. Further, all sets exist away from the 
extreme left boundary of PMI space, which has been shown to be the domain of combinatorial 
screening collections;4 this speaks to the success of the CtD approach as arriving at novel 
compound classes that are distinct from standard screening libraries. Finally, several of the 
synthetic routes achieve structures that are significantly more “sphere-like” than the parent 
compounds (e.g., G4, Q4, Q5), which could have potential implications for introducing biogenic 
bias to derivatives based on these scaffolds. 
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Figure 2.3: Principal Moment of Inertia (PMI) analysis designates gross shape category (rod, disc, sphere) based on 
axes of rotational inertia. A) PMI of CtD52 set grouped by parent compound: gibberellic acid derivatives (blue 
diamonds), adrenosterone derivatives (red squares), and quinine derivatives (green triangles). B-D) PMI synthetic 
paths for G-, A-, and Q-sets, respectively, with arrows connecting intermediates along synthetic routes; off-target 
compounds are listed individually. 
2.1.2.3 Utility and Conclusions 
 Principal Moment of Inertia (PMI) analysis represents a simple way to graphically depict 
the general shapes of structures in a chemical collection. It is computationally straightforward, 
requiring only software capable of 3D energy minimization and rotational moment of inertia (I1, 
I2, I3) calculation. Using just three descriptors (pmi-x, -y, -z or pmi-1, -2, -3 depending on the 
software), meaningful information can be gleaned about the diversity of structure shapes as well 
as the overall dimensionality of the structure set. However, because the input data set is so small 
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(only three interrelated descriptors per molecule), the ultimate utility of PMI as a method is 
limited. As the synthetic paths in Figure 2.3B-D suggest, minor synthetic transformations can 
result in large movement within the PMI space. This is illustrated more directly in Figure 2.4. 
Hypothetical model sets were designed to test the effect of ring distortion transformations on a 
structure’s location in PMI space. The two sets were structurally related, where Set B contains 
the structures in Set A with an additional ring. But whereas a cleavage reaction on the Set A 
parent results in a highly “linear” structure as might be expected, the added ring in the B Set 
seems to hold all the structures in the middle of the PMI space; this raises doubts about any 
conclusions drawn from a PMI analysis. From a logistical standpoint, PMI calculations first 
require that the structures be 3D energy minimized; this can add to the computational burden, 
particularly for large structure sets. More fundamentally, there is a certain ambiguity inherent in 
categorizing compounds according to gross shape. The same location in PMI space can be 
occupied by drastically different structures; in an extreme example, the compounds methane, 
cubane, adamantane, and C60-fullerene are all perfectly “sphere-like” and would reside at the 
upper right vertex of the PMI boundary. Therefore principal moment of inertia must ultimately 
be recognized as a qualitative depiction of structural trends and not an absolute measure of 
diversity; nevertheless it is based on calculated metrics and thus represents a move toward a 
more quantitative structural analysis. 
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Figure 2.4: Hypothetical model sets to test effect of ring distortion reactions on a structure’s location in PMI space. 
Left: Two structurally-related parent compounds (red) are subjected to ring expansion (green), ring cleavage 
(purple), or ring substitution (blue). Right: Associated PMI graphs for Set A (top) and Set B (bottom). 
 
2.1.3 Principal Component Analysis (PCA) 
2.1.3.1 PCA Concept and Justification 
 Advances in chemoinformatics software permit the facile calculation of scores of 
molecular descriptors for large collections of chemical structures. These descriptors can include 
purely physicochemical (structural) properties (e.g., molecular weight, polar surface area, 
heteroatom count) or predicted activities of pharmacokinetic relevance (e.g., solubility, blood-
brain barrier permeability). Depending on the number of descriptors and the size of the structure 
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library, these calculations can quickly generate huge amounts of data. Whereas PMI analyses 
were limited by the information content (Section 2.1.2, “Principal Moment of Inertia”), raw 
molecular descriptor calculations can present a cumbersome overabundance of data. One 
approach to managing such large datasets is a statistical tool called principal component analysis 
(PCA).5 This concept is depicted in Figure 2.5. Briefly, PCA entails a series of linear 
transformations on an n-dimensional dataset to arrive at n new, orthogonal, dimensionless axes 
(principal components) that encapsulate the majority of the data variance within the first two 
principal components (PC1 and PC2). In this way, data of high dimensionality can be 
represented on a 2D graph in what is essentially a projection onto an x-y plane. If the chosen 
descriptors vary significantly across the given structures, then PCA can reveal a clustering of the 
data. New information may then be gained concerning the relationships among the original input 
descriptors and thus the structures being described. 
 
Figure 2.5: Pictorial depiction of principal component analysis (PCA). Data of high dimensionality are subjected to 
linear transforms yielding two orthogonal principal component (PC) axes that encapsulate the majority of the data 
variance, allowing a two-dimensional representation of an n-dimensional dataset, and ideally resulting in some 
meaningful clustering of the data. 
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2.1.3.2 Incorporation of CtD52 Set into a Prior Literature Analysis 
 The hypothetical data clustering depicted in Figure 2.5 is obviously an idealized case for 
the sake of illustration; in practice, principal component analyses often yield single clusters of 
points that elude rapid interpretation. However, the use of PCA by the Tan group in 2010 yielded 
an intriguing result.6 Starting with a set of 127 compounds from a variety of sources and 
classifications, a PCA of 20 physicochemical properties revealed a significant separation 
between natural products and synthetic drugs (Figure 2.6A). Incorporating the CtD52 set into the 
original Tan set, two observations were made. First, each set of derivatives (i.e., the G-, A-, and 
Q-sets) clustered roughly around the parent natural product. Second, the G-set and A-set clusters 
seemed to align with the “natural product” cluster whereas the Q-set cluster aligned more closely 
with the “synthetic drug” cluster (Figure 2.6B). Notably, the inclusion of the CtD52 set did not 
greatly affect the location of the Tan data points from the original analysis, and the percent 
encompassed variance was similar in the two cases (72.7% Tan vs 77.0% Tan + CtD). These last 
points are meaningful because the output of PCA is highly sensitive to the input dataset; it is 
critical, then, that the variance and descriptor biplot (discussed in the next section) are similar 
when making comparisons between two PCA outputs. 
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Figure 2.6: Principal component analysis (PCA) graphs exhibiting clustering of compounds from different origins. 
A) Literature6 graph shows separation of synthetic compounds (“drugs”) and compounds that are either natural 
products or natural product derivatives (“natural products”). B) Inclusion of CtD52 into original 127-compound set 
demonstrates clustering of compound sets by parent compound and affiliation of CtD sets as either synthetic- or 
natural product-like. 
 To better interpret the results of the Tan PCA and the implications of including the CtD52 
set, biplot graphs were generated (Figure 2.7). In the context of principal component analyses, 
biplots give a graphical representation of the composition of the principal component axes.7 That 
is, the individual contribution of each input descriptor to PC1 and PC2 is given in vector form. 
This breakdown of the PCA by biplot generation allows for a better understanding of the data 
separation, and this technique has been applied to biological and medicinal systems.8 Essentially, 
the length of a descriptor vector indicates its weight, and the direction indicates which principal 
component axis it affects. (Side by side comparison of the biplots before and after CtD52 
inclusion, Figure 2.7A and 2.7B respectively, corroborate the notion that the CtD52 set did not 
greatly affect the Tan PCA.) Moreover, the biplot can reveal correlations between descriptors 
that in turn reveal redundancies in the descriptor input. For example, the descriptors “R”, “S”, 
and “nStereo” fall in the same location in the biplot and their vectors overlap; this is to be 
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expected, since the number of stereogenic centers would track with the number of (R)- and (S)-
centers. (In fact, this points to the futility in including all three descriptor counts.) Meanwhile, 
the descriptors “XLogP” and “ALOGPs,” both calculated octanol/water partition coefficients, 
can be seen to contribute to PC1 in the positive direction; this accounts for the horizontal 
separation of the “natural products” from the “synthetic drugs” since natural products tend to 
have lower ClogP values (discussed further in Section 2.2.3). By far the most significant 
descriptors are “RngAr” (aromatic ring count) and “nStMW” (number of stereogenic centers 
divided by molecular weight), which contribute with equal weight but opposite sign to PC2. 
These anti-correlated descriptors account for the vertical separation of the “natural products” 
from the “synthetic drugs” and in fact are primarily responsible for the distribution of the Tan set 
(as well as the incorporated G-, A-, and Q-sets). In other words, the biplot reveals the two 
primary descriptors most heavily weighted in the original PCA. The segregation of aromatic 
content and chiral content suggests that the main distinguishing feature in these sets is the 
hybridization state of the carbons; this will be discussed further in Section 2.2.2. 
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Figure 2.7: Biplot graphs showing descriptor influence on principal component axes PC1 and PC2. A) Descriptor 
weights for 127-compound set in original analysis (from Bauer, R. et al.,6 supplemental information). B) Descriptor 
weights for analysis containing original structures plus compounds from the CtD52 set. Vectors have been inserted 
for visual clarity. 
2.1.3.3 Application of PCA to Individual Libraries 
 As mentioned previously, the output of a PCA can depend greatly on the input structures 
and associated descriptors. To test whether this type of analysis could be applied to any arbitrary 
structure set, PCA was performed on the ChemBridge MicroFormat collection, a 150,000 
compound library in use at the UIUC High-Throughput Screening Facility. The biplot for this 
analysis is shown in Figure 2.8, and it illustrates several shortcomings of PCA as a general tool. 
First, since this structure set is 1000-fold larger than the Tan set, descriptors that are obtained by 
inspection (e.g., “RingSys”, the number of distinct ring systems) are impractical and must be 
eliminated. Second, highly weighted descriptors do not always contribute readily interpretable 
meaning to the analysis; in the biplot shown, PC2 is controlled by chlorine count, oxygen count, 
polar surface area (correlating with oxygen count) and hydrogen bond acceptors. While this may 
be eventually informative, it is not immediately intuitive. Third, no clustering is observed in the 
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PC scatterplot (not shown), since this is a relatively low-diversity collection. In this instance, the 
PCA contributes little insight into the relationship among the input descriptors. For such a large 
set, it would be more meaningful and informative to look at individual descriptors. This will be 
discussed further in Section 2.2.1. 
 
Figure 2.8: Biplot graph for PCA of the ChemBridge MicroFormat library (n= 150,000), a low-diversity screening 
collection. Vectors have been inserted for visual clarity. 
2.1.3.4 Utility and Conclusions 
 Principal component analysis (PCA) is a powerful statistical tool with the potential to 
distill intuitive meaning from huge sets of data. At first glance, this method seems to 
simultaneously address the stated goals of depicting both complexity (by encompassing large 
sets of descriptor data) and diversity (by displaying separation of structures according to primary 
descriptors). However, the resulting output data from PCA can often require even further 
interpretation, negating the utility of the method as a clarification aid.9-13 Whereas PMI analysis 
incorporated too little data, PCA runs the risk of attempting too much in one graph. The output is 
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also critically dependent upon both the input structures and the selection of descriptors. The 
successful application of PCA by the Tan group is a direct result of a having a diverse input 
structure collection that in turn determined PC axes with easily interpretable chemical meaning. 
Whether this compound selection was judicious or serendipitous, the Tan group certainly 
recognized its value, as it went on to incorporate unrelated structures into the previous set (in the 
same way as was done in this chapter’s analysis).14-15 PCA is therefore best applied to small, 
manageable, and diverse sets of compounds from which meaningful clustering can be observed 
and easily interpreted. 
 
2.2 Quantifying Complexity by Molecular Property Distributions 
2.2.1 Rationale for One-Dimensional Property Distributions 
Chemical screening libraries can contain anywhere from thousands to millions of unique 
structures. Accordingly, any attempt to calculate properties of the structures in a library will 
quickly generate vast amounts of data. As the previous sections illustrated, a balance between too 
little data and too much data is required for a successful analysis; either extreme risks being 
uninformative. Ultimately, the factors that must be considered are information density, clarity, 
and utility. Since descriptor calculation is a trivial matter, even for large data sets, a 1D 
histogram is a simple and elegant solution to a problem that is often made worse by 
unnecessarily complex techniques. A property profile is generated for a particular dataset (i.e., a 
compound collection) and that profile can then be easily compared to profiles of other sets.2, 10  
2.2.2 Calculating Complex Descriptors for Large Datasets  
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As mentioned in Section 2.1.3.3, it is preferable to restrict descriptor calculations to those 
properties that can be automatically analyzed in a software package. Even then, it is sometimes 
necessary to perform mathematical operations on calculated descriptors (in a spreadsheet 
program) to arrive at some desired meaningful descriptor. Examples of such complex descriptors 
include blood-brain barrier permeability prediction (combination of polar surface area and 
ClogP)16 and the previously discussed ratios of rotational moments of inertia for PMI shape 
analysis (see Section 2.1.2). One complex descriptor of particular interest is the overall s-p 
character of the carbons, as suggested by the principal component analysis (Section 2.1.3.2). 
Fraction sp3 (Fsp3) has been shown to be a useful descriptor in drug discovery, as a higher Fsp3 
tracks with higher likelihood of success in the clinic.17 Fsp3 is defined as the number of sp3 
carbons divided by the total number of sp3 and sp2 carbons:18 
 Fsp3=
൫nsp3൯
൫nsp3+ nsp2൯ 
While this formula is straightforward enough on a case-by-case basis, large structure sets do not 
lend themselves to manual inspection of carbon s-p character. Fortunately the valence of each 
carbon can be assessed computationally, which in Discovery Studio takes the form of an 
electrotopological state (E-state). This calculates a separate value for each of 13 types of carbon 
containing single (s), double (d), triple (t), or aromatic (a) bonds. Substituting the appropriate E-
state descriptors into the Fsp3 formula gives the following: 
Fsp3=
ሺsCH3+ssCH2+sssCH+ssssC	ሻ
ሺaaaC+aaCH+aasC+dCH2+ddC+dsCH+dssC+ sCH3+ssCH2+sssCH+ssssCሻ	
In this way fraction sp3 can be rapidly calculated for structure sets of any size. 
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2.2.3 Library Comparisons Using Molecular Property Distributions 
2.2.3.1 Descriptor Selection 
With the ability to represent molecular property profiles established, the selection of 
appropriate descriptors becomes the key factor in achieving informative comparisons. A report 
from 2011 examined compounds synthesized by medicinal chemists over the past 50 years, and 
compared them to marketed drugs according to several physicochemical descriptors.19 The 
authors observed several trends in pharmaceuticals that point to key descriptors for analysis. 
Notably, they observed an overall decline in the fraction sp3 (Fsp3) of carbons, and a higher-
than-ideal overall average ClogP. Accordingly, these two descriptors were chosen for the 
primary analysis in the original CtD manuscript. Since Fsp3 can be artificially boosted with 
peripheral long alkyl chains, number of stereocenters was also included as an additional metric 
for structural complexity.2 To complete the analysis here, the full set of standard 
physicochemical descriptors was profiled, and comprised the following properties: molecular 
weight (MW), topological polar surface area (PSA), physiological distribution coefficient 
(ClogD), number of rotatable bonds, number of hydrogen bond acceptors (HBA), and number of 
hydrogen bond donors (HBD). 
2.2.3.2 Library Selection and Comparisons 
Because the primary goal of CtD is to improve upon or complement existing screening 
collections, several chemical libraries were subjected to property distribution analysis. The first 
library chosen for comparison was the ChemBridge Microformat Library, a 150,000 compound 
set in use at the UIUC High-Throughput Screening Facility. This library has been discussed 
previously in the context of PCA (see Section 2.1.3.3) and contains high aromatic content as a 
result of its primarily synthetic origins. For a second comparison library, the set of FDA-
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approved drugs (1,519 compounds at the time of analysis) was chosen. The FDA set 
encapsulates all currently approved drugs and draws from both synthetic and natural sources. As 
a third set, the Analyticon NatX Library was selected. The NatX Library is a 24,800 compound 
set of semi-synthetic natural product derivatives designed by biology-oriented synthesis 
(BIOS).20-21 Generally this entailed an initial degradation of a natural product, followed by 
standard medicinal chemistry peripheral transforms to bring the degradation products up to a 
desired molecular weight. Since the NatX set combines standard med chem and natural products, 
it represents a good intermediary between origins (synthetic vs. natural) of the ChemBridge and 
the Complexity-to-Diversity sets. The descriptor distribution profiles are shown in Figure 2.9 
with the libraries arranged in rows by color in the following order: ChemBridge (first row, red), 
FDA (second row, green), NatX (third row, orange) and CtD52 (bottom row, blue). The 
distribution histograms are stacked and aligned by descriptor to allow for vertical comparisons of 
the descriptor profiles and the locations of the average values. Listed from left to right are 
molecular weight (MW), fraction sp3 (Fsp3), ClogP, number of stereogenic centers, topological 
polar surface area (PSA), physiological distribution coefficient (ClogD7.4), number of rotatable 
bonds, number of hydrogen bond acceptors (HBA), and number of hydrogen bond donors 
(HBD).  
The MW profiles say little about the four libraries. Unsurprisingly, both commercial sets 
hew closely to Lipinski guidelines with an average MW under 500 (371 for ChemBridge, 435 for 
NatX). CtD fits this as well (avg. 411), according to design by the synthetic chemists. The MW 
profile for the FDA set ventures into the higher weight range (avg. 371), but this is also to be 
expected since many high mass natural products are approved drugs. 
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The distribution profiles for ClogP tell a compelling story about the origin of the 
compounds in each set as well as the likelihood of bioactivity in the screening collections. 
Looking at the FDA drugs, ClogP values cover a wide range but average at 2.18. The synthetic-
dominated ChemBridge is shifted to the higher range of values with an average ClogP of 3.99, 
almost exactly at the cutoff of 4 that medicinal chemists seek to avoid. Meanwhile, the CtD and 
NatX sets, both originating from natural products, show average ClogP values well below that of 
ChemBridge (2.90 and 1.87, respectively). These lower partition coefficients speak to a higher 
hydrophilicity that tends to translate to better success in discovery efforts. 
The Fsp3 profiles reveal a stark difference between the ChemBridge library (avg. 0.23) 
and the CtD52 set (avg. 0.59), with the FDA and NatX libraries falling neatly between the two 
(avgs. 0.47 and 0.49, respectively). This correlates with the relative levels of natural product 
content and overall synthetic influence; for CtD the overall natural product influence on Fsp3 is 
high, and efforts were made to maintain the inherently high Fsp3 afforded by the natural product 
starting materials. This was less true for the NatX set, where the Fsp3 was diminished in the 
early degradation steps. The ChemBridge set is dominated by the products of combinatorial 
efforts and sp2-sp2 couplings and is unsurprisingly low in average Fsp3. And finally the FDA set 
consists of a mixture of synthetics and natural compounds and thus displays a wide Fsp3 range.  
The profiles for number of stereocenters again speak nearly directly to the influence of 
natural product content in each set. The combinatorially-derived ChemBridge has an average of 
0.24 stereocenters, with over 80% of the 150,000 compound set possessing zero centers. 
Conversely, the CtD set has an average of 5.17 since efforts were made to preserve or rearrange 
the core scaffolds, where much of the chiral content is held. The NatX set suffers from the 
degradation aspect, but still has an average number of 2.68 by virtue of starting with natural 
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products. And the FDA set is almost bimodal, with a large majority having one or no 
stereocenters but then with a significant fraction (of natural product-derived drugs) containing 
multiple stereocenters. 
The PSA profiles are notable mainly in that all four libraries are essentially in alignment, 
with the ChemBridge, FDA, NatX, and CtD displaying average values of 67.2, 87.9, 87.1, and 
79.2, respectively. It should be stated here that this alignment speaks to the success of the CtD 
project, since the commercial libraries were designed to match the property profiles of known 
drugs (as approximated by Lipinski guidelines) and the CtD set does the same. 
Distribution coefficient ClogD is a property similar to ClogP except that it takes into 
account the charge state of molecules at a physiological pH of 7.4. As with ClogP, lower values 
are generally regarded as being better, and it is significant that the ChemBridge set has the 
highest average with 3.61. The NatX set is in reasonable alignment with the FDA drugs, with 
average values of 1.21 and 1.52, respectively. CtD is intermediate with an average ClogD of 
2.62, but it should be noted that this is a full log value lower than ChemBridge, translating to a 
ten-fold greater hydrophilicity at physiological conditions. 
The property distributions for rotatable bonds are somewhat more resistant to immediate 
interpretation. By itself, the property count speaks to the inherent flexibility in a molecule, which 
could translate to more promiscuous binding of multiple protein targets; less rotatable bonds 
would translate to higher rigidity and potentially higher specificity in a given binding site. This 
analysis would be faulty, however, in that it ignores the shape and overall dimensionality of the 
molecule. When Fsp3 is considered along with rotatable bond count, a pattern emerges that 
speaks to the overall ring systems found in the various libraries. The ChemBridge set has low 
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overall Fsp3 (0.23) and a low average rotatable bond count (3.93), which speaks to the overall 
aromatic character of its chemical population. The FDA set has a high bond count (6.23) but the 
profile is broad; in the same way as with the broad Fsp3 profile (avg. 0.47), this speaks to the 
wide range of origins (from synthetic and natural sources) for the approved drugs. The NatX set 
has a relatively high Fsp3 (0.49) but a very high rotatable bond count (avg. 7.62), which speaks 
to the natural product core scaffolds that have been broken and diminished by the degradation 
steps of the BIOS. Meanwhile, CtD has the highest Fsp3 (0.59) combined with a relatively low 
rotatable bond count (avg. 4.67), which speaks to a tendency towards the complex multicyclic 
ring systems that characterize many of the CtD core scaffolds. 
Finally, the property profiles for HBA and HBD tell a similar story as the profiles for 
polar surface area. Commercial collections make an effort to hew to the profiles of known drugs 
for hydrogen-bonding, and this is seen in all four libraries. Average HBA for the FDA set is 
5.17, and the ChemBridge, NatX, and CtD sets approach this average with values of 3.75, 4.71, 
and 4.02, respectively. Meanwhile, average HBD for the FDA set is 2.16, and again the 
ChemBridge, NatX, and CtD sets approach this average with values of 1.08, 1.96, and 1.23, 
respectively. As with the distribution profiles for PSA, this speaks to the achievement of CtD as 
a means of arriving at compounds primed for success in discovery efforts. 
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2.2.4 Directing Synthesis by Molecular Property Distribution Profile Matching 
 This technique, while extremely informative for analyses of existing structures, can also 
be applied to proposed structures (Figure 2.10). In other words, new structures can be designed 
according to their predicted descriptor profile, with the goal of matching the profile of an 
existing set with known bioactivity. For example, O’Shea and Moser22 performed a study of 
physicochemical properties of known antibiotics. What they found is that the physiological 
distribution coefficient ClogD7.4 reflects activity against Gram-negative bacteria, with negative 
values being the best. Structure collection ClogD7.4 profiles are compared in Figure 2.10: 
ChemBridge (top, red), Gram-negative Antibacterials (middle, green), and Proposed CtD 
Structures (bottom, blue). These profiles show that a Gram-negative screen against the 
ChemBridge Library will have little chance of success. Meanwhile, the proposed CtD structures 
have a much greater likelihood of success, as evidenced by the overlap in ClogD7.4 profiles. 
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Figure 2.10: Directing synthesis by descriptor profile overlap. Shown are profiles for ClogD7.4 (distribution 
coefficient at physiological pH) for ChemBridge MicroFormat (red, n = 150,000), Gram-negative antibacterials 
(green, n= 112, from O’Shea and Moser23), proposed CtD structures (blue, n = 100). 
 
2.2.5 Utility and Conclusions 
 Molecular descriptor distribution profiles are a simple and elegant method for rapidly 
gaining insight into property makeup of a screening library. When combined with analyses of 
other libraries, comparison is both meaningful and facile. The best-looking histograms will result 
from the analysis of large libraries, but even small libraries are amenable to this approach (even 
if the profiles are less aesthetically pleasing). Finally, these descriptor profiles can be used as 
predictors of future success, by aligning profiles of proposed structure sets against known 
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libraries of known activity. This last point, where computational methods are being used to direct 
synthetic planning, is bearing out in current and ongoing efforts on the CtD project.  
 
2.3 Quantifying Diversity by Tanimoto Similarity 
2.3.1 Tanimoto Similarity and Chemical Structure 
The previous section covered the development of a quantitative approach to defining 
molecular complexity using molecular property distribution histograms. In a way, this approach 
begins to address the second main question of this chapter, that of molecular diversity. However, 
a descriptor-based approach to structural diversity is somewhat indirect. To directly address 
structural chemical diversity, a Tanimoto similarity metric was employed.23 Tanimoto similarity 
(Ts, also known as Jaccard similarity) is defined in terms of two binary data sets (A and B) as the 
ratio of the intersection over the union: 
Ts = 
| A ∩ B |
| A ∪ B | 
This is shown in Venn diagram form in Figure 2.11. Substituting into the previous equation gives 
Ts as: 
Ts =
C
(A + B - C)
	
This is obviously a very general scoring metric, applicable to any two data sets. In chemical 
terms, this is simply an expression of structural overlap between two molecules. However, there 
is considerable flexibility is the application of this scoring method, particularly in the conversion 
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of a chemical graph (i.e., a drawn-out molecular structure) and a data string suitable for 
comparison. This will be addressed in the following section. 
 
Figure 2.11: Venn representation of Tanimoto similarity. For two data sets A and B, the Tanimoto similarity score is 
given by the data intersection (C) divided by the data union (A+B-C). The score value ranges from 0 (no overlap) to 
1 (identical data sets). 
2.3.2 Molecular Fingerprints 
 To generate the data sets for comparison by Tanimoto similarity, extended connectivity 
fingerprints (ECFP) were employed.24 By this method, each atom in a molecule is individually 
analyzed and the surrounding atom connectivity is recorded. The extent of connectivity is 
programmable; ECFP_2, ECFP_4, and ECFP_6 involve a connectivity record of distances of 
one, two, and three bonds away, respectively (Figure 2.12). Each atom is assigned a unique 
numeric code by element, and the connectivities of all atoms are arranged in a matrix dubbed a 
“fingerprint” for comparison against another structure’s “fingerprint”. Chemically this can be 
interpreted as the construction of fragments; the more fragments two structures have in common, 
the higher the similarity score. This represents an advancement from historical substructure 
searches used by databases, as these relied on comparisons against a standard library of chemical 
fragments.25-26 Instead, ECFP offers a refined, tailored approach to permit the direct calculation 
of similarity scores between two compounds.  
A BC
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Figure 2.12: Representative construction logic of extended connectivity fingerprints (ECFP) from one carbon of 
benzamide. Box colors correspond to radii encompassing fragments of increasing size. A complete fingerprint 
would consist of fragments generated from every atom in the molecule. 
2.3.3 Tanimoto Similarity Based on Extended Connectivity Fingerprints 
2.3.3.1 Calibrating Tanimoto Similarity Score 
To demonstrate the Tanimoto similarity score in the context of the CtD compounds, 
hypothetical structures were designed based on peripheral transformations to the parent 
compounds G, A, and Q. These “non-core” transformations were intended to simulate the 
traditional modifications performed on natural products and specifically precluded any alteration 
of the core ring systems. The ECFP_6-based similarity scores associated with these simple 
changes are shown in Figure 2.13 (left, scores in red) and are relatively high, indicating only 
small differences from the parent natural product. Conversely, similarity scores for core scaffold 
ring distortion reactions are shown on the right (blue). These scores are all relatively low, 
indicating a large difference between the target compound and the parent natural product. 
Significantly, the three structures shown (G11, A6, and Q4) are obtained through a single 
synthetic step from the respective parents. Over the course of developing this method, ECFP_6 
fingerprints were found to result in scores that seemed to fit best with chemical intuition, likely 
because the larger fragments were most affected by the overall changes in the core scaffold. It 
should be noted, however, that while there are different methods for generating a similarity 
score, the numbers themselves have no intrinsic value. Therefore care should be taken when 
ECFP_2 ECFP_4 ECFP_6
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comparing discussions of similarity in the literature, as scores only have meaning relative to 
each other. 
 
Figure 2.13: Tanimoto similarity scores (ECFP_6) for peripheral vs. core scaffold transformations. Left: 
Hypothetical transformations that leave the core scaffold unaffected bear relatively high similarity scores to the 
parent compound. Right: Single-step ring distortion reactions yield altered core scaffolds with relatively low 
similarity scores to the parent compound. 
2.3.3.2 Application of Tanimoto Similarity to CtD52 Set 
To assess structural diversity across the complete set of target compounds (Figure 2.1B-
D), a similarity matrix was constructed by comparing each structure against all other structures 
(Figure 2.14). This matrix demonstrates that compounds in one set are highly different from 
compounds in another set, which is reasonable, because different sets originate from different 
natural product starting points. However, even within each structure set, high diversity is 
evidenced by the similarity scores. Comparing target compounds to their associated parent 
natural products, G set scores range from 0.09-0.38, A set scores range from 0.09-0.31, and Q 
set scores range from 0.20-0.30. 
ADRENOSTERONE
QUININE
GIBBERELLIC ACID
0.71
0.60
0.71 0.17
0.22
0.28
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Figure 2.14: Tanimoto similarity matrix for G, A, Q, and all associated target compounds. Heat map corresponds to 
Tanimoto score where 0 (blue) represents compound pairs with zero fingerprint overlap and 1 (red) represents 
identical connectivity. 
 The similarity matrix was taken further to include the entire CtD52 set (Figure 2.15). The 
justification for this analysis lies in a key feature of CtD: every intermediate along every 
synthetic route is a complex structure worthy of inclusion in a screening collection. In this larger 
matrix, the target compound sets are shown in the smaller boxes. Unsurprising, higher similarity 
scores are observed when comparing closely related intermediates; nevertheless, scores remain 
low between sets even with the inclusion of the additional intermediate structures. Note that 
since ECFP is based on 2D connectivity, diastereomers (e.g., A10 & A11, A5 & A15) appear to 
be identical. 
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2.3.3.3 Similarity Relationships by Hierarchical Dendrogram 
To more closely examine the relationships between compounds in the context of 
structural similarity, a hierarchical dendrogram was constructed (Figure 2.16). This is 
reminiscent of the phylogenetic trees used to depict evolutionary relationships, or homology 
diagrams that depict DNA sequence overlap. This dendrogram, which is based on the same 
ECFP_6-derived Tanimoto scores as used previously, was constructed to probe similarity 
clustering of the CtD52 set. The initial hypothesis was that the three sets, being derived from three 
distinct starting points, would fall into three clusters according to parent compound. However, as 
shown in Figure 2.16, assigning a cluster cutoff of 3 results in a large cluster consisting of 
structures from both the A and G sets. This jibes with the clustering observed in the PCA of the 
CtD52 set (see Section 2.1.3.2) in which there was significant overlap between these two sets. 
 
Figure 2.16: Hierarchical clustering dendrogram of CtD52 set depicting Tanimoto similarity based on ECFP_6 
molecular fingerprints. Three-cluster analysis (top) is insufficient to divide the set into its constituent parent groups, 
reflecting a similarity overlap between the A and G sets. Five-cluster analysis (bottom) sufficiently divides the set 
and reveals distinct subgroups within the A and G sets. Red dashed lines added to highlight cluster cutoffs. 
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2.3.4 Utility and Conclusions 
 Tanimoto similarity is a valuable tool for determining structural difference in a 
quantitative manner. It permits an objective analysis that corroborates the more subjective 
assessment of a chemist’s eye test. Care must be taken to calibrate the scoring methods to 
represent the data in a convincing way. As these scores have no intrinsic value, scores can only 
be compared when calculated by the exact same method; different similarity metrics and 
fingerprint methods exist, and can impact the output as much as the chemical structures. Finally, 
a Tanimoto score does not speak in any way to compound quality. Certainly there are instances 
where a structure set with high similarity and exhibiting subtle differences would be desirable 
(e.g., SAR studies for the development of a drug lead). However, in the context of evaluating the 
structural diversity of the CtD compounds, Tanimoto similarity was successful. 
 
2.4 Conclusions and Outlook 
The central theme of this chapter – quantifying and visually representing chemical 
change in a graphical manner – was developed in conjunction with a new synthetic effort in the 
Hergenrother group. By subjecting natural product starting materials to a series of ring distortion 
transformations, novel core scaffolds of high complexity and diversity can be rapidly achieved. 
Using simple and intuitive chemoinformatic tools, a subjective eye test has been replaced by 
objective and informative property histograms along with convincing and quantitative similarity 
scores. Moreover, these same tools can be used both to describe past syntheses and to direct 
future synthetic efforts. Though only three natural products were discussed here, the Complexity-
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to-Diversity (CtD) project is ever-expanding; to date over 220 novel compounds have been 
synthesized from seven starting natural products.   
 
2.5 Materials and Methods 
2.5.1 General 
Calculations and analyses were conducted using a range of chemical, informatic, and 
statistical software including ChemDraw (CambridgeSoft, Cambridge, MA), MOE (Chemical 
Computing Group, Montreal, Quebec, Canada), Discovery Studio (Accelrys, San Diego, CA), 
Canvas (Schrödinger, New York, NY), R (http://www.r-project.org), and Excel (Microsoft, 
Redmond, WA). All work was done on desktop and laptop computers without the use of a 
computing cluster. 
2.5.2 Library Data Files 
Library collection data were acquired as Structure-Data Format (.sdf) files where 
available. Structural data for ChemBridge MicroFormat Library (n = 150,000), Illinois HTSF 
Library (n = 4,700), and Illinois Marvel Heritage Collection (n = 10,000) were obtained through 
the University of Illinois High-Throughput Screening Facility (Urbana, IL: 
http://scs.illinois.edu/htsf/compound_collections.html). Data on FDA-approved drugs (n = 
1,519) were obtained via e-LE3D at the Institute for Molecular and Cellular Pharmacology 
(Nice, France: http://chemoinfo.ipmc.cnrs.fr). Data for the NATx natural-product semi-synthetic 
derivative library (n = 24,800) were obtained from Analyticon (Potsdam, Brandenburg, 
Germany: http://www.ac-discovery.com/content/Products&Technologies/NatDiverse.php). 
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Synthesized (i.e., CtD), or literature-compiled (e.g., antibacterial, anticancer) structure lists were 
generated in ChemDraw, then organized in MOE and saved as .sdf files. 
2.5.3 Principal Moment of Inertia Analysis 
Principal moment of inertia (PMI)3 values were calculated in MOE after minimizing 
structures to their most energetically favored 3D conformation (MMFF94x). Ratios of the 
resulting normalized moment of inertia values I1, I2, and I3 (from MOE descriptors “pmi1”, 
“pmi2”, and “pmi3” respectively) were plotted in Excel, with (I1/I3) as the x-axis plotted from 
0.0 to 1.0, and (I2/I3) as the y-axis plotted from 0.5 to 1.0. Synthetic paths were generated by 
calculating PMI for intermediate structures, ordering the data sequentially in Excel, and 
connecting the graphed data points with an arrow line. The PMI function boundary was plotted 
using a connected 4-point data set consisting of [0, 1], [1, 1], [0.5, 0.5], and [0, 1].  
2.5.4 Principal Component Analysis 
The protocol for the principal component analysis (PCA) follows that outlined by Bauer 
et al.6 Molecular property descriptors for the CtD structure set were generated in MOE, 
Discovery Studio, and by inspection. Descriptors were then entered into an Excel spreadsheet 
with compound names in the first column (no heading) and all descriptor values listed in 
subsequent columns (with descriptor headings). In a separate worksheet, all descriptor values 
were internally normalized to a range of 0 to 1 based on the minimum and maximum values for 
each descriptor, where valuenorm = (value – MIN)/(MAX – MIN). All numerical values were 
formatted as numbers with 4 decimal places, and the resulting worksheet was saved as a text file 
to be processed in R. Cumulative variance, principal component (PC) values, and biplots were all 
generated in R. PC1 and PC2 were graphed in Excel as an X-Y scatterplot. 
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2.5.5 Molecular Property Distribution Histograms 
The modeling software package MOE was used to calculate stereocenter counts 
(“chiral”), topological polar surface area (“tPSA”), rotatable bond counts (“b_rotN”), hydrogen 
bond acceptor counts (“a_acc”), and hydrogen bond donor counts (“a_don”). All other molecular 
properties were calculated in Discovery Studio using the Analyze Small Molecules toolset. Fsp3 
values were calculated using the electrotopological state (E-State) counts for all 13 possible 
carbon configurations according to the formula: 
Fsp3=
ሺsCH3+ssCH2+sssCH+ssssC	ሻ
ሺaaaC+aaCH+aasC+dCH2+ddC+dsCH+dssC+ sCH3+ssCH2+sssCH+ssssCሻ	
Histograms were generated in Excel using the Data Analysis ToolPak. Histogram bin values 
were chosen based on the minimum and maximum values in arbitrarily chosen increments 
ranging from ten to twenty. 
2.5.6 Tanimoto Similarity Analysis 
Library .sdf files were generated in ChemDraw and organized in MOE. Tanimoto 
similarity coefficients were calculated using Discovery Studio. Each structure was saved as an 
individual .sdf file in ChemDraw and used as an input reference ligand for the Library Analysis 
protocol “Find Similar Molecules by Fingerprints”, setting the minimum similarity to 0 and 
using ECFP_6 molecular fingerprints. This was repeated for all compounds and the resulting 
Tanimoto coefficients were arranged in a similarity matrix. Heatmaps were generated in Excel 
using a three-color scale set to 0.0 (blue), 0.5 (yellow), and 1.0 (red). Hierarchical clustering 
dendrograms were generated in Schrödinger Canvas based on Tanimoto scoring of ECFP_6 
fingerprints, with the number of clusters set to 3 and 5. 
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CHAPTER 3: HIGH-THROUGHPUT SCREEN (HTS) FOR SMALL-
MOLECULE INHIBITORS OF RNA-PROTEIN COMPLEXATION IN 
TYPE 1 MYOTONIC DYSTROPHY (DM1) 
 
3.1 Development of DM1 Inhibition Screen 
 As part of a larger effort in the Hergenrother group to target RNA secondary structure, an 
assay and screen were developed to discover new small molecules capable of binding RNA 
internal loops. In the pursuit of this goal, type 1 myotonic dystrophy (DM1) was chosen as a 
disease model. This disease involves an aberrant expansion of r(CUG) repeats that forms a 
ladder of sequential 1×1 U-U internal loops; this RNA ladder binds the splicing regulatory 
protein MBNL1, sequestering it to the cell nucleus and preventing MBNL1 from performing its 
splicing function on various target pre-mRNAs in the cytoplasm.1-3 This loss of MBNL1 function 
results in a host of disease symptoms, all of which ultimately arise from the deleterious 
poly(CUG)-MBNL1 binding event. Apart from the purely clinical relevance, the selection of this 
model was based on previous collaborative efforts between the Hergenrother and Cunningham 
groups. Capitalizing on a previous high-throughput screen (HTS) for inhibitors of a DNA-protein 
interaction,4 a screen for RNA-protein interaction inhibitors was envisioned. This screen was 
intended to complement simultaneous efforts in the Zimmerman and Baranger groups based on 
rational inhibitor design and biophysical studies, respectively. This chapter will explore the 
development and execution of a screen for novel small-molecule binding inhibitors of 
poly(CUG)-MBNL1 and the validation assays surrounding the resulting screening hits.  
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3.1.1 Photonic Crystal Biosensor as Screening Platform 
 The photonic crystal (PC) biosensor as developed in the Cunningham group5-7 is an ideal 
system for the development of a screen for DM1 inhibitors. Briefly, the PC consists of a 
fabricated polymer grating overcoated with a material of high refractive index (e.g., TiO2); upon 
illumination by a broadband light source, a narrow band of light is reflected with a characteristic 
wavelength determined by the local refractive index at the sensor surface. Since the PC biosensor 
technology effectively measures changes in biomass on a surface, inhibition of complex 
formation between two large biomolecules can be observed without the need for a fluorescent 
marker or colorimetric readout. It was hypothesized that for a model DM1 system, inhibitors 
would bind the repeating internal loops of the poly(CUG) RNA ladder to effect a disruption of 
the RNA-protein complex. This approach is summarized in the context of the PC technology in 
Figure 3.1: the sequential formation of an RNA surface and an RNA-protein complex surface 
would be measurable by the shift in peak wavelength value (PWV) of light reflected from the 
sensor. These PWV shifts can be monitored in real-time to give a kinetic data output (Figure 
3.2), and data acquisition can be paused for addition of material (e.g., inhibitor or protein 
solutions) to the plates. Endpoint data are referenced against control wells within the plate to 
account for non-specific binding events. Finally, the instrument incorporates a moving stage to 
permit high-throughput data collection in a multiwell plate format. 
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Figure 3.1: Schematic of DM1 screen using a photonic crystal biosensor. Sensor surface (blue) is functionalized 
with a target RNA (red) to which a cognate protein binds (green) except in the presence of an inhibitor compound 
(orange). All interactions are measured by shifts in the peak wavelength value (PWV) of light reflected from the 
sensor material. 
 
Figure 3.2: Generalized kinetic plot on photonic crystal biosensor. Active trace (red) results from addition of a 
ligand or biomolecule with significant binding affinity to a capture element on the surface. Reference trace (blue) 
results from non-specific interactions between ligands and an unmodified sensor surface. Dashed lines indicate a 
pause or incubation step. 
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3.1.2 Selection of RNA Construct for DM1 Model 
3.1.2.1 Previous Literature Studies with “CUG4” 
In selecting an RNA sequence for a high-throughput screen (HTS), a balance must be 
achieved between two opposing criteria. On one hand, a long sequence of poly(CUG) would 
most accurately model the uncontrolled triplet expansion of the DM1 disease state; on the other 
hand, such long sequences are expensive to purchase or time-consuming to manufacture. 
Previous work by Berglund8 appeared to achieve such a balance: in vitro gel-shift studies 
employed a 17-base oligonucleotide containing two (CUG)2 sequences flanking a UUCG quartet 
(5’-G(CUG)2UUCG(CUG)2-3’, nominally “CUG4,” Figure 3.3). The UUCG quartet is well-
characterized as forming an “ultrastable” tetraloop hairpin,9 and so CUG4 was graphically 
depicted as containing two consecutive U-U mismatch 1×1 internal loops. Further, this short 
sequence was reported to bind MBNL1 with comparable affinity to a sequence containing 90 
(CUG) repeats (Kd ~170 nM vs ~260 nM, respectively). From 
these data the authors surmised that the CUG4 construct 
represented the shortest possible model for the U-U mismatches 
characteristic of poly(CUG). However, the very presence of the 
UUCG tetraloop represents a deviation from the mRNA found in 
the disease state. Additionally, when this sequence was 
submitted to mFold for secondary structure calculation,10 a 
different folding pattern was predicted than that reported by 
Berglund, bearing a single 1×1 internal loop and a pentaloop 
hairpin (Figure 3.3, contrast “CUG4*” with “CUG4”). Moreover, 
even with the UUCG tetraloop in place, it is unlikely that the remaining nucleotides would fold 
Figure 3.3: Folding patterns for 
RNA constructs used in this 
study (CUG4* as reported by 
Berglund;8 all others calculated 
by mFold). 
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as reported without a stabilizing CG stem; the resulting construct would be dominated by single-
strand, non-duplexed RNA, devoid of the internal loop ladder displayed in naturally-occurring 
DM1 RNA. With this discrepancy between the published and calculated folding patterns in 
mind, two other poly(CUG) constructs were examined: one bearing three U-U mismatches (5’-
GG(CUG)8CC-3’, hereafter “CUG8”) and another bearing five U-U mismatches (5’-
GG(CUG)12CC-3’, hereafter “CUG12”). These two constructs were designed to be more 
reflective of the DM1 genotype; the stabilizing element for these lies in the two-base CG stem, 
and mFold predicts a regular patterning of U-U mismatch 1×1 internal loops (Figure 3.3).  
3.1.2.2 Stability of RNA Surface on PC Biosensor  
When working with RNA, there is a constant danger of RNA degradation by 
environmental RNase contaminants. Therefore, there was an initial concern as to whether the PC 
biosensor could provide a stable environment allowing for the detection of surface-bound RNA. 
However, overnight incubation of biotin-labeled CUG4, CUG8, and CUG12 to a streptavidin-
coated surface revealed consistent PWV shift signals commensurate with oligonucleotide base-
length; i.e., the longer the sequence, the greater the PWV shift (Figure 3.4). Importantly, these 
signals were stable and persistent over a timescale of days (not shown), validating the 
experimental environment for RNA work and allowing sufficient time to perform the assay.  
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Figure 3.4: Representative PWV shifts for overnight incubation with biotin-labeled RNA constructs of increasing 
length to streptavidin-coated PC biosensor surface. Error bars represent standard deviation (n = 3). 
3.1.2.3 Variable Binding of MBNL1 to RNA Constructs 
Initial MBNL1-binding tests involving the CUG4, CUG8, and CUG12 constructs showed 
an unexpected trend in binding signals. Whereas CUG8 and CUG12 consistently tracked at the 
same PWV shift against a given protein concentration, the same protein against CUG4 displayed 
significantly higher signal (Figure 3.5). This would seem to be a point in favor of using the 
CUG4 construct (higher presumably offering superior signal-to-noise), but subsequent 
competitive inhibition tests led to the elimination of this construct as a usable species. When the 
surface-bound biotinylated constructs were pretreated with ten-fold excess of unlabeled 
construct, the trials involving CUG8 and CUG12 both displayed full loss of signal whereas the 
CUG4 only exhibited partial loss (Figure 3.6). This may have been due to undesired binding 
interactions brought about by the UUCG sequence or an interaction involving the purported 
pentaloop hairpin in the CUG4 construct. Given this failure to meet the competitive inhibition 
benchmark, the inapplicability of the sequence to the disease model, and the general uncertainty 
surrounding the CUG4 folding pattern, the CUG4 construct was dropped from further 
consideration for this assay.  
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Figure 3.5: PWV shift upon addition of 10 μM MBNL1 to RNA constructs CUG4, CUG8, and CUG12. Shift values 
are relative to that of surface-bound RNA alone. Error bars represent standard deviation (n = 3). 
 
Figure 3.6. Competitive binding of MBNL1 to surface-bound poly(CUG) by free RNA. RNA surfaces were 
generated by treatment of 10 µM biotin-RNA to streptavidin (SA2) sensor plate and incubation overnight at 4 °C. 
Plate was washed and treated with 10 μM MBNL1 pre-incubated with 100 µM unlabeled RNA. PWV shift values 
are relative to that of surface-bound RNA alone. Error bars represent standard deviation (n = 3). 
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3.1.2.4 CUG8 versus CUG12 
The fact that MBNL consistently bound to the CUG8 and CUG12 constructs with 
comparable PWV shift deserves special mention. Structurally, little is presently known about the 
precise nature of MBNL1 binding to poly(CUG) RNA. However, the mere fact that severity of 
the disease phenotype tracks with (CUG)-repeat length suggests that an increased MBNL 
binding signal should be anticipated for longer poly(CUG) constructs. This expectation did not 
hold here, or, at least, there was no significant difference in signal between constructs bearing 
three or five U-U mismatch 1×1 internal loops. One explanation may be that an increase of two 
mismatches does not significantly affect length of the poly(CUG) hairpin, where length would 
correlate to accessibility to MBNL1 (no crystal structures of MBNL1 currently exist that would 
allow for modeling simulations to test this hypothesis). Another explanation may involve the 
technical limits of the PC biosensor. The signal relies on resonance with an evanescent standing 
wave within the photonic crystal; a consequence of this evanescence is that binding events must 
be in close proximity to the PC surface to effect a shift in the reflected peak wavelength (i.e., 
signal decreases exponentially with increasing distance from the surface). Therefore, there may 
be an upper limit to the length of poly(CUG) that can be practically utilized in this system. Either 
hypothesis could be tested by using longer and longer (CUG)-repeat lengths, but these are 
tangential concerns to be investigated at a later date. Looking ahead to the primary goal of 
developing a robust assay, the CUG8 construct was ultimately chosen based on the fact that the 
more costly construct (CUG12) did not significantly increase signal. Thus CUG8 was the 
minimal structure required for robust, repeatable signal in this assay. 
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3.1.3 MBNL1 Binding to an RNA Surface 
3.1.3.1 Dual-tagged Truncated MBNL1 (GST-MBNL1N-His6) 
Previous literature studies have made use of a truncated form of MBNL1 (hereafter 
“MBNL1N”) that displayed comparable poly(CUG) binding affinity while maintaining greater 
stability in solution relative to the full-length MBNL1.8, 11 As stated above, no crystal structure 
for MBNL1 currently exists; however, primary sequence analysis shows that the first 260 
residues contain two pairs of zinc finger domains that are required for RNA-binding activity.11 
The truncated MBNL1N encompasses these 260 residues and is illustrated in Figure 3.7. 
MBNL1N was expressed as an N-terminal glutathione S-transferase (GST) fusion protein with a 
C-terminal (His)6 tag, allowing for dual purification of the protein by sequential Ni-NTA and 
GST affinity columns followed by enzymatic cleavage of the GST tag. Initial studies using the 
PC biosensor employed dual-purified MBNL1N stocks provided by Sreeni Ramisetty in the 
Baranger group. However, binding signal from this protein tended to be lower than desirable; 
moreover, the dual purification seemed to have a considerable negative effect on expression 
yield. In an effort to increase expression yields (and boost PC signal through the use of a protein 
of higher mass), the GST purification step was omitted. This resulted in the use of a GST-
MBNL1N-His6 fusion protein, which has previously been shown to bind poly(CUG) RNA.11 
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Figure 3.7: Full length vs truncated MBNL1. The first 260 residues encompassed by MBNL1N contain the four 
necessary zinc finger domains (shown in orange) and are therefore sufficient for activity. For this study, MBNL1N 
dual-labeled with GST (purple) and hexa-Histidine (pink) was employed. Figure adapted from Warf and Berglund.8  
3.1.3.2 Demonstration of MBNL1N Binding 
Using truncated, tagless MBNL1N, a dose-dependent increase in signal was observed for 
binding to a CUG8 surface (Figure 3.8), and non-specific binding to the streptavidin surface was 
minimal. However, the maximum signal increase was seldom more than 1-1.5 nm in PWV shift; 
previous studies on the PC biosensor suggested that a greater signal should be expected for a 
comparable protein surface-binding event.5 Moreover, the signal showed no saturation as would 
be needed to determine the limits of the system (and thus an EC50 value). Switching to the GST-
MBNL1N-His6 fusion protein addressed both issues, since the added mass from the GST tag 
boosted signal while the increased yields allowed for a higher concentration of protein to be 
tested (Figure 3.9). Analysis by MALDI-MS confirmed that the fusion protein GST-MBNL1N-
His6 (MW: 56.3 kDa) was being stably expressed and that any low-weight contaminants were 
being removed by the centrifugation spin column purification step (see Section 3.7.3). From 
these data, EC50 was estimated at 5 μM GST-MBNL1N-His6; this concentration of fusion protein 
was used for all subsequent experiments. 
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Figure 3.8: Early efforts at demonstration of MBNL1 dose-dependence. Truncated, tagless MBNL1 (MBNL1N, 
residues 1-260) was added to a CUG8 RNA surface. MBNL1N exhibits increased binding signal with increased 
concentration, but fails to achieve saturation. Average PWV shifts (relative to RNA surface) are given above each 
column, with error bars representing standard deviation (n = 3). 
 
Figure 3.9: MBNL1 dose-dependence and signal saturation were achieved using a GST-MBNL1N-His6 fusion 
protein (EC50 ~5 μM). Fusion protein was added to a CUG8 RNA surface. All PWV shift values are relative to the 
RNA surface, with error bars representing standard deviation (n = 3). 
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3.1.3.3 RNA Sequence Selectivity 
The ability to demonstrate sequence selectivity of MBNL1 for poly(CUG) was critical to 
this assay, as it would rule out the possibility of promiscuous RNA-binding of MBNL1. In other 
words, the dose-dependent increase in binding signal of GST-MBNL1N-His6 must be dependent 
upon the presence of poly(CUG) for the assay to be a relevant method to locate small molecule 
binders to poly(CUG). Previous in vitro studies showed a lower affinity of MBNL1 for binding 
poly(CAG) RNA and almost no affinity for binding duplex RNA.8, 11 Gratifyingly, this trend was 
reflected in the PC biosensor, with the GST-MBNL1N-His6 fusion protein yielding a similar 
affinity profile (Figure 3.10).  
 
Figure 3.10: Sequence selectivity of GST-MBNL1N-His6 binding to various RNA surfaces. PWV shift upon 
addition of 10 μM GST-MBNL1N-His6 to CUG8, CAG8, and duplex surface-bound RNA constructs. Shift values 
are relative to that of surface-bound RNA alone. Error bars represent standard deviation (n = 3). 
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3.1.4 Establishing Assay Control Treatments 
3.1.4.1 Competitive Inhibition by Unlabeled RNA 
Initial tests indicated that free RNA would fully compete away MBNL1-binding to 
surface RNA (see Section 3.1.2). Initial attempts at dose-dependent loss of signal showed only 
modest levels of inhibition. However, by increasing the maximum concentration of free RNA, 
full loss of binding signal was achieved with a 100-fold excess of free RNA to GST-MBNL1N-
His6 (Figure 3.11). This high free RNA concentration requirement may be a result of a 
procedural difference between this assay and the previous PC biosensor assay involving a DNA-
protein interaction.4 In the case of the DNA screen, small molecules or free DNA were pre-
incubated with protein; this mixture was then added to the surface-bound DNA. However, in the 
case of the RNA assay, it was desirable to bias the screen towards binders for poly(CUG) rather 
than binders of MBNL1, since poly(CUG) RNA is the purported toxin and binders to MBNL1 
may have deleterious effects on its ability to mediate splicing processes. Therefore, small 
molecules (and free RNA) were added to the surface-bound RNA first, followed by addition of 
GST-MBNL1N-His6. 
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Figure 3.11: Competitive binding of 5 μM GST-MBNL1N-His6 fusion protein to surface bound biotin-CUG8 by 
addition of increasing concentrations of free (unlabeled) CUG8. PWV shift values are relative to that of surface-
bound RNA alone. 
3.1.4.2 Inhibition by Melamine-Acridine Conjugates 
Work by Jonathan Arambula in the Zimmerman group yielded compound 1 (Figure 
3.12), combining two approaches to nucleic acid binding in order to achieve specificity for RNA 
displaying a U-U mismatch 1×1 internal loop (or the analogous T-T mismatch in DNA).12  
 
Figure 3.12: Control compounds for small-molecule inhibition. 
The melamine serves as a “Janus wedge” to a U-U mismatch by providing 
complementary hydrogen-bond donors and acceptors to the uracil on each “face” (Figure 3.13). 
Meanwhile the acridine moiety derived from the antimalarial quinacrine serves as a general 
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intercalating agent.13 A linker consisting of 4 methylene units was determined to be optimal for 
binding the 1×1 internal loop U-U mismatch. Compound 2 differs from 1 only in the 3 
methylene unit linker, yet was shown to bind the target RNA with lower affinity. Compound 3, 
in which the melamine is absent, binds with significantly lower affinity.14 
 
Figure 3.13: Melamine moiety displays hydrogen-bond complementarity to RNA (U-U) mismatch while the acridine 
acts as a general intercalator. This conjugate is therefore well-suited to have affinity for nucleic acid duplexes with 
specificity for U-U RNA (or T-T DNA) mismatches. 
Initial PC biosensor inhibition experiments with these compounds consisted of treatment 
of CUG8-coated wells with 100 μM stock solutions followed by 10 µM GST-MBNL1N-His6, 
using treatment with 100 μM unlabeled CUG8 as the inhibitory control. The resulting endpoint 
data is shown in Figure 3.14. Compellingly, whereas 1 inhibited MBNL1 binding to a level 
comparable to that of the free RNA, 2 inhibited binding to a lesser extent, while 3 showed no 
inhibition with a signal comparable to GST-MBNL1N-His6 binding alone.  
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Figure 3.14: Inhibition of MBNL1-CUG8 binding upon treatment with 100 μM control compound 1. Shown for 
comparison are PWV shift signals from 10 µM GST-MBNL1N-His6 alone, competition with 100 μM free CUG8, 
and compounds 2 and 3. Error bars represent standard deviation (n = 3). 
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3.1.5 Finalizing Assay Conditions for HTS 
3.1.5.1 Determining Optimal RNA Surface Conditions 
Since this work relied on the use of purchased RNA, a balance was required between the 
cost of starting materials and the amount of RNA required to exhibit consistent, significant 
binding signals on the sensor plate. With this in mind, streptavidin-coated PC biosensor wells 
were incubated overnight with increasing concentrations of biotin-labeled CUG12 RNA (Figure 
3.15a). Peak wavelength value (PWV) shifts reached a plateau of 1.8 nm at RNA concentrations 
above 12.5 μM, with ~95% saturation at 10 μM. Treatment of these same wells with 5 μM GST-
MBNL1N-His6 protein showed a PWV shift plateau occurring above RNA concentrations of 
6.25 μM (Figure 3.15b). As mentioned previously in Section 3.1.2.3, MBNL1 was shown to bind 
CUG8 and CUG12 with similar affinity. Therefore these data validated previous use of 10 μM 
biotin-labeled RNA, and CUG8 RNA was used at a concentration of 10 µM throughout all 
subsequent experiments. 
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Figure 3.15: a) Saturation of a streptavidin-coated photonic crystal biosensor surface with biotin-labeled poly(CUG) 
RNA. b) Treatment of varying levels of RNA-saturation with constant concentration (5 μM) of GST-MBNL1. PWV 
shift values are relative to PBS buffer. Error bars represent standard deviation (n=3). Note that although CUG12 
RNA was employed in these tests, previous experiments would suggest nearly identical outcomes with CUG8 RNA. 
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3.1.5.2 Determining Optimal GST-MBNL1N-His6 Treatment 
Previous experiments demonstrated a dose-dependent signal increase upon increasing 
concentrations of GST-MBNL1N-His6 to a poly(CUG) RNA surface. These experiments were 
repeated using the optimized RNA surface conditions (Figure 3.16). As is the case with the RNA 
used in these studies, care must be taken to balance the supply of protein against effective and 
reproducible signal in the assay. While the use of GST-MBNL1-His6 at concentrations in the 
plateau region would give the highest and most reliable PWV shifts, such high concentrations in 
this assay are unnecessarily wasteful. With regard to signal, consistency within a sensor plate is 
of paramount importance; accordingly, protein concentration was always constant across a given 
plate. Nevertheless, it was desirable to maintain consistent results from plate-to-plate; thus GST-
MBNL1N-His6 concentration was maintained at 5 μM throughout all subsequent screening 
experiments. 
 
Figure 3.16: Dose-dependence of GST-MBNL1N-His6 binding to poly(CUG) RNA surface. A 10 μM solution of 
poly(CUG) RNA was used to generate the surface. PWV shift values are relative to RNA surface. Error bars 
represent standard deviation (n=9). 
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3.1.5.3 Buffer pH Considerations 
Previous work involving DNA-protein studies on the PC biosensor proved to be highly 
sensitive to changes in buffer pH.4 To investigate the effect of pH in this RNA-protein assay, 14 
buffer solutions were prepared with pH values ranging from 5.5 to 7.5. As shown in Figure 3.17, 
lower pH correlated with higher binding signal, most likely due to increased electrostatic 
interactions between the protein and the RNA phosphate backbone upon protonation of amino 
acid residues. In the case of the DNA-protein system, robust binding was not observed in neutral 
conditions, necessitating slightly acidic (pH 6.3) conditions. In the case of the RNA-protein 
system studied here, there was sufficient signal at pH 7.0 to merit continued work at a pH more 
reflective of physiological conditions. All subsequent studies employed buffer at neutral pH. 
 
Figure 3.17: Effect of pH on nucleic acid-protein binding signal on photonic crystal biosensors. PWV signals are 
relative to nucleic acid-bound surface. Error bars for poly(CUG) RNA-GST-MBNL1N-His6 represent standard 
deviation (n=3). CUG8 RNA was used at 10 μM; GST-MBNL1N-His6 was used at 5 μM. DNA-AIF literature 
values are taken from Chan, L. et al.4 
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3.1.6 Preliminary Screen Tests 
3.1.6.1 Needle-In-A-Haystack Experiment 
With optimized conditions (i.e., RNA and protein concentrations, pH, see above) in hand, 
attention was turned to the HTS. To assess the ability of the PC biosensor assay to discern a “hit” 
compound from assay noise, compound 1 was tested against 18 single-compound wells sampled 
at random from the Marvel Library (plate 7). Compound 1 was designed to bind DNA T-T 
mismatch internal loops14 and has been shown to bind analogous RNA U-U mismatch internal 
loops.12 PC biosensor experiments also indicate that 1 inhibits the poly(CUG) RNA-MBNL1 
interaction, as 100 μM of 1 gives a ~1.0 nm PWV drop in the optimized poly(CUG) RNA-GST-
MBNL1N-His6 binding experiment (Figure 3.18), allowing 1 to be easily discerned from other 
compounds that do not inhibit this interaction.  
 
Figure 3.18: Needle-in-a-haystack experiment. Compound 1 (samples #5 and #14, red) was easily distinguished 
from other compounds in the Marvel Library. Compounds (100 μM) were added to poly(CUG) RNA-surface and 
incubated for 2h; GST-MBNL1N-His6 (5 μM) was then added and incubated for 6 h. PWV shift values are relative 
to RNA-surface (sample #1) with compound. Error bars represent standard deviation (n=3). (* p < 0.05) 
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3.1.6.2 Calibrating Free RNA as Positive Inhibition Control 
The needle-in-a-haystack experiment revealed that compound 1 stood on its own when 
compared to other single compounds. As the experiments moved closer to the multiplexed 
conditions that would be used in the HTS (e.g., employing 10 compounds per well), compound 1 
became less useful as a positive control. The main problem was one of aqueuous solubility. To 
achieve consistent inhibition results in the poly(CUG) RNA-MBNL1 assay, a high concentration 
(>100 μM) of 1 is required, but making these high concentrations in PBS requires a higher 
amount of DMSO (10%) than is allowable on the PC biosensor, which is sensitive to changes in 
refractive index. At HTS conditions, compound 1 exhibits ~25% inhibition of binding signal 
relative to untreated GST-MBNL1N-His6, whereas unbiotinylated poly(CUG) RNA gives >50% 
inhibition (see Figure 3.21, below). Importantly, poly(CUG) RNA directly competes with the 
RNA on the surface for MBNL1 binding, as it represents an exact mimic to the MBNL1 binding 
target in the DM1 disease state. Further, it should be possible to enhance the inhibition level of 
the unlabeled poly(CUG) RNA simply by using longer poly(CUG) repeats. With this in mind, 
compound 1 was shelved as a positive control in favor of unlabeled poly(CUG) RNA at 10-fold 
excess to the surface RNA. From this positive control, applied to each individual sensor plate, 
normalized percent inhibition data were calculated. 
3.1.6.3 Mini-Screen Employing Multiplexed Compound Wells 
The final test before continuing on to the screen proper was to run the assay at full HTS 
conditions. Specifically, this entailed the use of compound plates containing ten compounds per 
well; the incorporation of automated robotic liquid-handlers in place of manual pipetting; and the 
full adoption of all standardized controls. The first such test is shown in Figure 3.19. 
Gratifyingly, the test wells exhibited a baseline inhibition level near 0% with a narrow range 
79 
 
(~10% inhibition) of values indicating low noise, while one lone test well stood apart from the 
rest as a false positive. This result was sufficient to move forward into the full screen. 
 
Figure 3.19: Inhibition data from initial “mini-screen”. Eighteen test wells containing 10 compounds per well (50 
μM in PBS, 0.5% DMSO) were screened against unbound poly(CUG) RNA (100 μM, red) as the positive control 
(set at 100% inhibition). Compound and protein were added sequentially with 2h and 6h incubations, respectively. 
Compound wells were tested in duplicate and GST-MBNL1 binding was measured relative to surface-RNA plus 
compound. Sample #16 (circled) is a false positive in this test. 
3.1.6.4 Signal Variation in Initial Screening Plates.  
The promising result from the test screen (Sections 3.1.6.1 and 3.1.6.3) allowed the work 
to progress into full test plates. Systematic error was immediately apparent, as evidenced by a 
downward sloping of the data (Figure 3.20, first two data sets). While the plate-by-plate nature of 
the screen made a certain amount of variation between plates to be expected (compare the first 
two data sets to the third), such a trend within a data set was alarming. The one reassuring aspect 
of these first two plates was that the compound replicates were consistent; each compound well 
was run in duplicate and replicate PWV shift values were consistently <0.1nm in difference. For 
this reason duplicate wells were dropped to allow for higher compound throughput per plate and 
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reduce overall material requirements for the screen. Initial attempts to optimize the protocol and 
reduce the in-plate noise focused on incubation times. In these early plates, shorter incubation 
times for both compound and protein (0.5 h and 2 h, respectively) yielded more consistent data 
(Figure 3.20, third data set).  
 
Figure 3.20: Inhibition data from first ~3200 compounds tested. Separate sensor plates are denoted by red dashed 
lines. All inhibition data is normalized to the free RNA positive control (first data point per set) present as an 
internal control in each plate. Note plate-to-plate variation as well as internal noise/error in these initial attempts. 
3.1.6.5 Assessing Noise Levels by Dummy Plates 
A “blank” test plate containing only DMSO in PBS buffer was carried through screening 
conditions to assess inherent noise in the system (Figure 3.21a). Particularly unsettling was the 
presence of a false positive at ~95% inhibition. However, this is partly explained by the original 
PWV shift data from the biosensor instrument (Figure 3.21b). In this case, a higher concentration 
of GST-MBNL1N-His6 (10 μM instead of 5 μM previously) was used to raise signal on average 
and reduce random noise; an undesired consequence was that the free RNA positive control 
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exhibited a lower inhibition value. Since all other inhibition data is normalized to the positive 
control, the inhibition data is intrinsically linked to this value. Increasing the separation between 
the positive and negative controls (i.e., free poly(CUG) RNA and uninhibited MBNL1, 
respectively) is the key to narrowing the baseline variation of calculated inhibition values, 
making “hit” samples more apparent. 
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Figure 3.21: a) “Inhibition” data from dummy screen of a multiwell plate containing only DMSO (0.5%) in PBS 
buffer. Compound and GST-MBNL1N-His6 protein were added sequentially with 0.5 h and 2 h incubations, 
respectively. Values are normalized to inhibition by unlabeled CUG8 RNA (100% positive control). Data point 133 
(circled) is an outlier. b) PWV shift data from which inhibition data is calculated. Values are relative to CUG8 RNA 
surface (first entry, baseline). Shown in red is GST-MBNL1N-His6 (10 μM) alone without compound, while in 
green is GST-MBNL1N-His6 (10 μM) treated with 100 μM unlabeled CUG8 RNA. Outlier point 133 (circled) is 
visible as a diminished PWV shift. 
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3.1.6.6 Optimizing Baseline Signal Variation by Altering Incubation Times 
Although the HTS conditions had been optimized to avoid signal drift (as in the first 
plates), there remained the issue of a certain “standard” noise level as illustrated above in Figure 
3.21a. Separate studies involving a PC biosensor screen for DNA-protein inhibitors suggested 
that a long protein incubation might address this by allowing the protein to fully equilibrate with 
the poly(CUG) RNA surface.15 To test this, two sensor plates were subjected to identical 
compounds and conditions, with only the protein incubation time altered. In the first case, the 
previous HTS incubation times of 0.5 h and 2 h (for compound and protein, respectively) were 
employed; in the second case, the protein incubation time was extended to 12 h with the plate 
sealed and stored at 4 °C. The inhibition data showed that whereas the shorter incubation (Figure 
3.22a) results in basal noise level around 40%, the level drops to around 0% upon longer 
incubation (Figure 3.22b). Gratifyingly, a compound well which presented as a hit under the first 
set of conditions remained after the longer incubation.  
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Figure 3.22: Inhibition data from ~1600 compounds tested under two different incubation conditions. a) Compound 
incubation for 0.5 h was followed by protein incubation for 2 h at room temperature. b) Compound incubation for 
0.5 h was followed by protein incubation overnight at 4°C. Longer incubation results in similar range of signals but 
with lower average basal level. Note that sample #126 manifests as a hit in both cases, warranting further 
examination. Data normalized to competitive free RNA (positive control, red) and DMSO (vehicle control, yellow). 
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3.1.6.7 Assay Development – Summary 
 Development of the RNA-protein inhibition assay into a full screen required extensive 
optimization of reagent concentrations, buffer conditions, and incubation timing. Translating the 
assay from individual tests performed by micropipette to a high-throughput method employing 
automated robotic liquid handlers introduced additional complications of signal variation and 
noise. Even after troubleshooting the assay to function at the multiwell plate level, there 
remained considerable variability in signal from plate to plate. This issue, which is evident 
throughout the primary HTS data (Section 3.2), originates from a supply-chain issue in the 
screening reagents. Specifically, the GST-MBNL1N-His6 protein had to be expressed and 
purified in separate batches. Stockpiling the protein was not an option since it was observed to 
degrade and lose binding activity after a period of ~2 weeks of storage in PBS buffer at 4 °C. 
Such issues are often addressed through the use of stabilizers such as glycerol, but the high 
refractive index of glycerol interferes with the optical readout on the PC biosensor. Ultimately 
the solution was the inclusion of in-plate controls (i.e., competitive free RNA and DMSO 
vehicle) to which all test compounds were normalized. Accepting this plate-to-plate variability 
was necessary for the progression of the screen, and hits were assessed based on relative 
normalized inhibition values. 
 
3.2 HTS and Primary Results 
3.2.1 Marvel (Heritage) Library 
The first screening set employed in the DM1 HTS was the Marvel Library, a collection of 
~10,000 compounds synthesized over the past 50 years at the University of Illinois at Urbana-
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Champaign.16 This collection was assembled from leftover compounds in storage and includes 
large quantities of solid chemical stocks. As such it was an ideal “starting set” for the screen, and 
compound plates from the Marvel Library were employed during many of the development 
stages of the HTS (Sections 3.1.6.1, 3.1.6.3, 3.1.6.4, and 3.1.6.6). Primary data from the screen 
of this library are shown in Figure 3.23. Compounds were multiplexed to nine per well at a 
screening concentration of 100 µM, and the full collection was screened over seven sensor 
plates.  
 
Figure 3.23: Primary inhibition data for photonic crystal biosensor screen of Marvel (Heritage) Library tested over 
seven plates. Each data point represents 9 multiplexed compounds. Inhibition data are normalized to competitive 
free RNA (positive control, red) and DMSO (vehicle control, yellow).  
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3.2.2 HTSF Contributed Collection 
Continuing the tradition of the Marvel Heritage Library, the University of Illinois High-
Throughput Screening Facility (HTSF) curates submitted compounds from labs in the Chemistry 
department as well as from labs outside the university. The collection is ever-expanding, but at 
the time of this screen it comprised ~5,000 compounds. Primary data from the screen of this 
library are shown in Figure 3.24. Compounds were multiplexed to seven or eight per well at a 
screening concentration of 100 µM, and the full collection was screened over two sensor plates. 
 
Figure 3.24: Primary inhibition data for photonic crystal biosensor screen of the HTSF Contributed Collection tested 
over two plates. Each data point represents 8 multiplexed compounds. Inhibition data are normalized to competitive 
unlabeled RNA (positive control, red) and DMSO (vehicle control, yellow).  
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3.2.3 Boger Distamycin Combinatorial Library 
A collection of ~9,000 compounds from the Boger lab (Scripps) was also tested. This 
consisted of a combinatorial collection based on distamycin A, a natural product predisposed to 
DNA minor-groove binding.17 Compounds were multiplexed to ten per well at a screening 
concentration of 50 µM, and this collection was screened over three sensor plates. Primary 
screening data are shown in Figure 3.25. 
 
Figure 3.25: Primary inhibition data for photonic crystal biosensor screen of distamycin-based Boger combinatorial 
collection17 tested over three plates. Each data point represents 10 multiplexed compounds. Inhibition data are 
normalized to competitive free RNA (positive control, red) and DMSO (vehicle control, yellow).  
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3.2.4 ChemBridge MicroFormat Library 
Finally, the bulk of the HTS was performed with the MicroFormat Library, a 150,000-
compound commercial screening collection available from ChemBridge.18 Primary data are 
shown in Figure 3.26. Compounds were multiplexed to ten per well at a screening concentration 
of 100 µM, and the full collection was screened over 47 sensor plates. 
 
 
Figure 3.26: Primary inhibition data for photonic crystal biosensor screen of ChemBridge MicroFormat Library. 
Each data point represents 10 multiplexed compounds. Each subsequent color group denotes an individual screening 
plate (47 in total). Inhibition data are normalized to competitive free RNA (positive control, 100%) and DMSO 
(vehicle control, 0%).  
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3.2.5 Deconvolution of Multiplex Hits 
 Primary multiplex hits from the DM1 HTS were retested in multiplex. Those sets that re-
hit were then deconvoluted into their constituent individual compounds. Unique hit compounds 
were immediately apparent when comparing inhibition signals among a given multiplex set 
(Figure 3.27). Of the 27 multiplex re-hits, 19 yielded single individual hits and one yielded two 
individual hits. For the seven multiplex re-hits that yielded no individual hits, the possibility of 
synergistic effects was briefly considered but ultimately not pursued. As summarized in Table 
3.1, the entire HTS began with ~180,000 compounds and yielded 77 primary multiplex hits, 27 
multiplex re-hits, and finally 21 individual hit compounds. The structures for the 21 individual 
hits are shown in Figure 3.28 and include compounds from the Marvel Library, the HTSF 
Contributed Collection, and the ChemBridge MicroFormat library. 
 
Figure 3.27: Representative deconvolution experiment showing PC biosensor endpoint binding data for repeat-
multiplex hits separated into constituent individual compounds. First three bars (red) represent RNA surface, 
MBNL, and free RNA control. All subsequent color groupings represent separated multiplex sets. Error bars 
represent standard deviation (n = 3). 
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Table 3.1: Summary of DM1 HTS. Fifty-two plates comprising ~180,000 compounds were screened from the 
ChemBridge (red), Marvel (green), and HTSF (orange) libraries, yielding 77 primary multiplex hits. These were 
retested to yield 27 multiplex rehits that were then deconvoluted to yield 21 individual hit compounds. 
 
Screen Plate CB Plates Multiplex Hits Re‐Hits Deconvolution Screen Plate CB Plates Multiplex Hits Re‐Hits Deconvolution
I 1‐10 4 1 (M21) 0 XXVIII 271‐280 0
II 11‐20 3 1 (D7) 1 (CB16.D7) XXIX 281‐290 2 (B11, J6) 0
III 21‐30 0 XXX 291‐300 4 (A8, B6, L14, P21) 0
IV 31‐40 2 2 (D16, E12) 1 (CB35.E12) XXXI 301‐310 0
V 41‐50 1 0 XXXII 311‐320 2 (D9, J13) 1 (D9) 1 (317.D9)
VI 51‐60 3 1 (C7) 1 (CB59.C7) XXXIII 321‐330 3 (A3, A5, N5) 1 (N5) 1 (321.N5)
VII 61‐70 5 (D13, H16, H20, J9, L9) 0 XXXIV 331‐340 1 (B12) 1 (B12) 1 (338.B12)
VIII 71‐80 3 (E6, H20, O6) 0 XXXV 341‐350 0
IX 81‐90 1 (E22) 0 XXXVI 351‐360 0
X 91‐100 4 (C4, D22, G20, I12) 2 (D22, I12) 2 (93.D22, 96.I12) XXXVII 361‐370 0
XI 101‐110 1 (G11) 1 (G11) 1 (103.G11) XXXVIII 371‐380 2 (J19, K22) 1 (J19) 1 (376.J19)
XII 111‐120 0 XXXIX 381‐390 2 (P15, P18) 1 (P15) 1 (383.P15)
XIII 121‐130 0 XL 391‐400 2 (M6, N20) 0
XIV 131‐140 0 XLI 401‐410 0
XV 141‐150 4 (E22, G22, J8, P20) 0 XLII 411‐420 0
XVI 151‐160 1 (F3) 1 (F3) 1 (160.F3) XLIII 421‐430 0
XVII 161‐170 2 (A10, A11) 2 (A10, A11) 0 XLIV 431‐440 0
XVIII 171‐180 1 (J7) 1 (J7) 0 XLV 441‐450 0
XIX 181‐190 1 (B4) 1 (B4) 0 XLVI 451‐460 1 (A11) 0
XX 191‐200 0 XLVII 461‐469 1 (K10) 1 (K10) 1 (469.K10)
XXI 201‐210 1 (E17) 1 (E17) 0
XXII 211‐220 0 Screen Plate Plates Multiplex Hits Re‐Hits Deconvolution
XXIII 221‐230 1 (H9) 0 ML 1 1‐9 5 3 (A4, L22, M22) 3 (6.A4, 9.L22, 9.M22)
XXIV 231‐240 0 ML 2 10‐18 3 2 (J4, J20) 2 (10.J4, 12.J20)
XXV 241‐250 0 ML 3 19‐28 2
XXVI 251‐260 1 (G9) 0 HTSF 1 1‐8 3 1 (P8) 2 (5.P8, 6.P8)
XXVII 261‐270 2 (N9, O14) 0 HTSF 2 9‐15 2 1 (J13) 1 (10.J13)
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Figure 3.28: Deconvoluted hit compounds from DM1 HTS displaying repeatable inhibition activity by PC biosensor 
assay. Compound designations indicate library (ChemBridge, Marvel, HTSF) and location within library (plate 
number and microwell ID). NB: stereochemical assignments are unavailable for Marvel 6.A4, HTSF 6.P8, and 
HTSF 10.J13. 
 
3.2.6 False Positive Elimination 
3.2.6.1 Dose-Response Experiments 
 The set of 21 hits was further refined to identify compounds demonstrating strong, dose-
responsive inhibition within the PC biosensor assay. For these experiments, all compound 
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solutions were freshly prepared from solid stocks; for ChemBridge hits, compounds were re-
purchased. Compound solutions were prepared as 100 µM stocks and serially diluted in steps of 
75% to cover a range of 16 concentrations from 1 µM to 100 µM. A representative data set for 
assessing dose-response is shown in Figure 3.29, in which only CB383.P15 emerged as a strong 
hit at lower concentrations. Of the 21 individual hits, six compounds satisfied this dose-response 
condition (Figure 3.30) and were advanced for further study. 
 
Figure 3.29: Representative PC biosensor dose-response tests for individual hits from DM1 HTS. First three bars 
(red) represent RNA surface, MBNL, and free RNA control. All subsequent color groupings represent hit 
compounds at increasing concentrations (75% serial dilutions from 100 µM [i.e., 1.3, 1.8, 2.4, 3.2, 4.2, 5.6, 7.5, 
10.0, 13.3, 17.8, 23.7, 31.6, 42.2, 56.2, 75, 100 µM]). For the given data set, compound CB383.P15 alone 
demonstrates strong dose-responsive inhibition at low concentration. Error bars represent standard deviation (n = 3). 
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Figure 3.30: Hit compounds from the DM1 HTS that exhibited strong, dose-responsive inhibition. 
3.2.6.2 Aggregation and Promiscuity Tests 
Compound aggregation is a major concern in HTS and can be a primary cause of false 
positives.19 Aggregator “activity” in inhibition assays is generally characterized by a binary 
dose-activity profile, and the gradual dose-response exhibited by the six lead compounds (section 
3.2.6.1) was encouraging. However, to fully allay suspicions of aggregator effects, the six lead 
compounds were reassessed on the PC biosensor in the presence of detergent.19-21 Tween 
detergent was added to the assay buffers at increasing concentrations (0.01%, 0.05%, and 0.1%). 
Separately, inhibitor RNA- and protein-binding promiscuity was ruled out by the inclusion of 
competitor tRNA and protein.22-23 This involved adding tRNA (at 5-fold base excess) or bovine 
serum albumin (0.1 mg/mL) to the compound solutions. Results from these tests are summarized 
in Figure 3.31. The presence of detergent had little effect on GST-MBNL1N-His6 binding to the 
CUG8 RNA surface, while the addition of BSA or tRNA had a minor effect on GST-MBNL1N-
His6 binding. Encouragingly, dose-responsive inhibition was not affected by the addition of 
detergent, BSA, or tRNA. This response profile was identical for all six lead compounds. 
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Figure 3.31: Representative aggregation and promiscuity tests in the PC biosensor DM1 inhibition assay. Red bars 
represent GST-MBNL1N-His6 binding to the CUG8 surface in the presence of BSA, Tween detergent, tRNA, or 
unlabeled CUG8. Subsequent bars represent tests of compound CB338.B12 at the indicated concentration in the 
presence of no competitor (blue), BSA (yellow), Tween detergent (green), and tRNA (purple). Error bars represent 
standard deviation (n = 3). 
3.2.6.3 Off-Target Enzyme Inhibition Tests  
 To corroborate the promiscuity experiments, Dr. James Heeres tested the lead compounds 
for inhibition activity in a panel of enzyme assays that included chymotrypsin, caspase-3, and β-
lactamase.19, 24 Each of these assays contains a modified substrate that gives a colorimetric 
readout upon cleavage by the targeting enzyme. These assays were run in the presence and 
absence of the HTS lead compounds, and the results are summarized in Table 3.2. Although 
none of the compounds inhibited chymotrypsin, two (CB321.N5 and CB469.K10) showed 
inhibition of caspase-3, while four (CB59.C7, CB321.N5, CB383.P15, and HTSF10.J13) 
showed inhibition of β-lactamase. The addition of detergent to the caspase-3 assay yielded no 
change, so inhibition could not be attributed to compound aggregation (while the β-lactamase 
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assay already included detergent). These results were somewhat troubling, but they did not 
warrant immediate elimination of the compounds for further study. At this stage, however, 
decisions regarding compound progression were largely based on potential for synthetic 
derivative generation (see Section 3.3).  
 59 321 338 383 469 HTSF 
Chymotrypsin --- --- --- --- --- --- 
Caspase-3 --- INHIB --- --- INHIB --- 
C3 + Triton-X --- INHIB --- --- INHIB --- 
β-Lactamase INHIB INHIB --- INHIB --- INHIB 
 
Table 3.2: Off-target inhibition of the DM1 HTS lead compounds in an enzymatic activity panel. 
 
3.3 Derivative Libraries from HTS Hits 
 To improve upon lead compound activity and probe potential structure-activity 
relationships (SAR), derivative libraries were synthesized. The selection of lead compounds for 
derivatization was based largely on the ease of planning divergent synthetic routes to allow for 
maximum diversification. With that in mind, compounds CB59.C7 (hereafter 59), CB338.B12 
(hereafter 338), and CB469.K10 (hereafter 469) were chosen for the synthesis of derivative 
libraries. While the structural similarity between compounds CB321.N5, CB383.P15 was 
compelling, failures in the off-target assays (Section 3.2.6.3) combined with limited possibilities 
for diversification led to their removal. Derivative libraries are summarized in Figure 3.32, with 
points of diversification indicated in red. Fifty derivatives were generated in total, 5 based on 59 
(Figure 3.33), 15 based on 338 (Figure 3.34), and 30 based on 469 (Figure 3.35). These libraries 
were taken forward into secondary assays (Section 3.4). All compounds were synthesized by Dr. 
Seok-Ho Kim with the exception of 338-15, which was synthesized by Dr. Isak Im. 
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Figure 3.32: Summary of derivative libraries based on HTS hits. Diversification points are indicated in red.  
 
 
Figure 3.33: Synthetic derivatives of hit compound 59. 
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Figure 3.34: Synthetic derivatives of hit compound 338.  
 
99 
 
 
Figure 3.35: Synthetic derivatives of hit compound 469.  
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3.4 Secondary Assays  
3.4.1 Surface Plasmon Resonance (SPR) 
 Numerous analytical biophysical techniques were employed to validate the hits from the 
DM1 HTS and assess derivative libraries. First among these was surface plasmon resonance 
(SPR), a microfluidics-based optical biosensor.25-28 Although SPR lacks the throughput 
capabilities of the PC biosensor, the flow cell technology permits real-time kinetic readings from 
which thermodynamic binding data can be determined. Further, dozens of test ligands can be 
sequentially flown over the same activated surface, theoretically validating comparison among 
measurements. As a control, all test ligands are simultaneously flown over an unactivated surface 
as reference to account for non-specific interactions on the sensor surface (analogous to the PC 
biosensor example in Figure 3.2). To assess direct binding of ligands to poly(CUG) RNA, a 
biotin-labeled CUG8 solution was injected on a streptavidin (SA) functionalized sensor chip 
until a saturation response level was achieved. As a positive control, compound 1 was flown over 
both RNA and SA channels in a series of increasing concentration injections, and resulting 
sensograms were subtracted. As shown in Figure 3.36A, compound 1 demonstrates dose-
dependent binding directly to the RNA. Test ligands from all three derivative libraries were all 
sequentially flown over both the RNA and SA surfaces. As represented by the resulting 
sensograms for 338-1, no significant RNA binding was observed for any compound from the 
DM1 HTS (Figure 3.36B). Hit compounds were then assessed in an RNA-protein inhibition 
assay akin to the original PC biosensor assay. In this setup ligand and MBNL1 were 
preincubated and the resulting solution was flown over the poly(CUG) RNA surface. The results 
of tests for 59-1, 338-1, and 469-1 are shown (Figure 3.37). By this technique, 469-1 shows 
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minimal inhibition, 59-1 shows strong inhibition, and 338-1 shows complete ablation of MBNL1 
binding.  
 
Figure 3.36: SPR sensograms to assay direct ligand binding to a poly(CUG) RNA surface relative to an unmodified 
streptavidin surface. A) Compound 1, demonstrating dose-dependent binding signal. B) Compound 338.1, 
demonstrating no binding over tested concentration range. Signal traces shown have been reference-subtracted. 
 
Figure 3.37: SPR sensograms for RNA-protein inhibition tests. Solutions containing pre-incubated ligand and 
MBNL1 were flown over a poly(CUG) surface and a reference streptavidin surface. Injections occur the first 60 sec. 
Signal traces shown have been reference-subtracted. 
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3.4.2 Isothermal Titration Calorimetry (ITC) 
 In a simultaneous effort to assay RNA binding of the HTS hits, isothermal titration 
calorimetry (ITC) was employed. In this technique, test ligand is serially injected into two 
thermally insulted chambers, one of which contains the target RNA while the other serves as a 
thermal reference. As the ligand interacts with the RNA, heat of binding is released and 
measured by the instrument. Sequential injections yield less heat of binding until saturation is 
achieved. Measured heat output is then converted into binding data. As expected from previous 
ITC experiments against a single U-U mismatch,12, 29 compound 1 was also shown to bind the 
poly(CUG) RNA in solution; however, no other compound exhibited binding by this method 
(Figure 3.38). 
 
Figure 3.38: Isothermal titration calorimetry to assess small molecule RNA binding. CUG8 RNA (20 µM) was 
treated with compounds 1, 59-1, 338-1, and 469-1 (500 µM) over 20 injections at 24 s intervals, with 300 s delays 
between each injection.  
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3.4.3 Phosphorous-32 Radiometric Electrophoretic Mobility Shift Assay (EMSA) 
 Gel-shift assays have long been the mainstay for nucleic acids research. In an 
electrophoretic mobility shift assay (EMSA), migration of an RNA along a gel is perturbed by 
interactions with binding partners. For DM1 models, this allows for interesting biophysical 
studies that dissect the relationship between MBNL1 and its RNA binding partners. 8, 30 It also 
permits the study of inhibitors of RNA-MBNL1 binding, again by monitoring the location of the 
RNA.12, 31 Here, a 32P isotopically-labeled RNA is incubated with protein and inhibitor and then 
run on an acrylamide gel. Bands near the top of the gel indicate complexation with GST-
MBNL1N-His6, whereas bands near the bottom of the gel have been released from GST-
MBNL1N-His6 binding by an inhibitor. Figure 3.39 shows nine derivatives in the 338 set in this 
EMSA. Densitometry analysis measures the “darkness” of a given band and allows 
quantification of inhibition (Figure 3.39, bottom). In a serendipitous result, it was observed that 
the 338 set of compounds were fluorescent under UV illumination (Figure 3.40). The locations 
of the fluorescent ligands correspond exactly to the locations of the radiolabeled RNA. These 
data seem to validate 338-1 as an inhibitor, and they further implicate the derivatives 338-3, 338-
4, 338-8, and 338-9. Notably, the compounds not exhibiting activity in this assay (338-2, 338-5, 
338-6, and 338-7 all share a similar structural feature in the lack of a carboxylic acid on the left 
side (see Figure 3.34). These results support the necessity of the carboxylic acid moiety for 
activity. Meanwhile, the full sets of derivatives based on compounds 59 and 469 showed no 
activity by this assay. 
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Figure 3.39: Radiometric EMSA with derivatives based on compound 338. Top: Autoradiograph indicating location 
of 32P-labeled RNA in the gel. Bottom: Densitometry analysis of the free RNA band allows quantitation of 
inhibition activity. 
 
 
Figure 3.40: Photograph of radiometric EMSA gel under UV illumination. UV fluorescence of 338 derivatives 
reveals location within the gel. Compound location was commensurate with RNA migration, with hits 338-1, -3, -4, 
-8, and -9 colocalized with the free radiolabeled RNA. 
N
or
m
. %
 In
te
ns
ity
 
105 
 
3.4.4 Fluorometric EMSA 
 Concurrently with the radiometric EMSA experiments, a fluorometric EMSA was 
developed. This was done in an effort to increase assay throughput, given the lengthy procedures 
involved in the radiometric assay. The use of a purchased fluorescently labeled RNA obviated 
the need to perform 32P-labeling reactions. Further, 32P has a half-life of ~14 days, and so 
experiments with labeled RNA must be carried out rapidly to avoid decay of the radioisotope; 
this limitation is also avoided with fluorescent compounds. Finally, experiments were run on 
small commercially available gels to circumvent the time-consuming process of casting and 
drying the relatively larger gels used in the radiometric EMSA. Imaging and analysis were 
analogous to the radiometric method, and representative gel data is shown in Figure 3.41. The 
primary drawback of the fluorometric EMSA was one of sensitivity, and larger amounts of RNA 
and protein were required for the fluorescent gels. Nevertheless, the ease of the assay permitted 
the rapid reassessment and validation of compounds showing activity in the radiometric EMSA. 
 
Figure 3.41: Representative fluorometric EMSA on pre-cast acrylamide gel. Left: Gel image showing loss of RNA-
protein complex band with concomitant increase of free RNA band upon increasing concentration of inhibitor. Fl-
CUG8 alone (R) and Fl-CUG8 + GST-MBNL1N-His6 without treatment (C) served as control lanes. Right: 
Densitometry analysis permits identification of EC50 concentration at intersection of “complex” and “free RNA” 
traces. 
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3.4.5 Fluorescence Titration Assay 
 In a secondary effort to directly assess compound RNA binding, fluorescence titration 
experiments were performed by Dr. Stacie Richardson using a method developed in the Baranger 
group.30, 32-33 Briefly, test compounds were titrated into a cuvette containing fluorescently labeled 
CUG12 RNA, and changes in fluorescence intensity were measured. Intensity values were then 
fit to calculate binding constants (Figure 3.42). Based on results from the radiometric EMSA, 
compounds 338-1, 338-4, 338-8, and 338-9 were tested in this fluorescence binding assay to 
reveal Kd values ranging from 29.7-43.5 µM (Table 3.3). 
 
Figure 3.42: Representative data from fluorescence titration assay. Test ligands were titrated into a UV cuvette 
containing fluorescently-labeled CUG12 RNA. Change in fluorescence intensity (left) can be curve-fitted to 
determine Kd values (right). 
Compound Kd (µM) 
338-1 43.5 ± 1.8
338-4 31.4 ± 3.0
338-8 31.4 ± 3.7
338-9 29.7 ± 2.8
 
Table 3.3: Calculated Kd values for compounds assessed by fluorescence titration. All compounds were tested in 
triplicate, with standard deviations given. 
107 
 
3.5 Cell Studies 
3.5.1 Toxicity by Sulforhodamine B (SRB) Assay 
 Compounds selected for advancement to cell studies were first assayed for toxicity. 
Based on the results of previous assays (see previous sections), the 338-derived library was 
screened against HeLa cells over 72 h, and toxicity was assayed by sulforhodamine B. As shown 
in Figure 3.43, the majority of the compounds were toxic at 100 µM. Further, two of the 
compounds precipitated from cell media and thus prevented accurate toxicity assessment. IC50 
toxicity assays were run for compounds exhibiting insolubility or >50% toxicity. These data are 
summarized in Table 3.4 and were used to determine the upper concentration limit of compound 
treatments in confocal microscopy experiments (section 3.5.2). 
 
Figure 3.43: HeLa toxicity screen of 338 derivative set. All compound treatments were at 100 µM for 72 h, and 
toxicity was assessed by SRB. Asterisks (*) indicate compound precipitation in cell media. Error bars represent 
standard deviation (n = 5).  
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Compound IC50 Compound IC50 
338-1 39.5 µM 338-11 35.2 µM
338-4 17.9 µM 338-12 40.8 µM
338-8 21.6 µM 338-13 22.0 µM
338-9 23.4 µM 338-14 32.1 µM
 
Table 3.4: HeLa toxicity IC50 values (72 h SRB) for 338 derivatives selected from the initial toxicity screen. 
 
3.5.2 Fluorescence Laser Confocal Microscopy 
3.5.2.1 Immunohistochemical Staining of Primary DM1 Cells.  
One of the hallmarks of the DM1 phenotype is the colocalization of MBNL1 with 
poly(CUG) RNA in discrete foci within the nuclei of affected cells. Previous studies have 
employed immunofluorescent methods to demonstrate both this colocalization as well as a return 
to a normal phenotype (characterized by MBNL1 dispersion).1, 3, 34 Here, MBNL1 was visualized 
by immunohistochemical staining in order to demonstrate formation of nuclear foci in primary 
DM1 fibroblasts (Figure 3.44a,b). Briefly, this was achieved by growing the cells on glass 
coverslips, fixing with paraformaldehyde, permeabilizing with Triton detergent, and then 
staining with fluorescent antibodies. As a non-DM1 control line, healthy human fibroblasts 
(Hs888Lu) were shown to express diffuse nuclear MBNL1 (Figure 3.44c). To see if a purported 
poly(CUG) RNA binder would have an effect on MBNL1 localization, DM1 cells were treated 
with compound 1 prior to fixation and staining. Unfortunately, even at the highest concentration 
of treatment (100 μM), nuclear MBNL1 foci were still present in the cells (Figure 3.44d) and 
occurring with the same frequency as in the untreated DM1 cells. As a control to determine 
whether the compound’s native fluorescence was affecting the microscopy images, DM1 
samples were treated with 1 and were fixed without fluorescent staining. Whereas untreated, 
109 
 
unstained cells were impossible to visualize under lasing conditions, cells treated with 1 
exhibited a faint fluorescence at 488 nm and 543 nm (Figure 3.44e). This low-level fluorescence 
did not interfere with the fluorescence of the antibody stain; in fact this experiment demonstrated 
visualization of the cell without additional staining and confirmed that the compound was 
entering the cell. Importantly, the lack of disruption of MBNL1 nuclear foci does not prove a 
lack of in vivo poly(CUG) binding, nor does it disprove inhibition of RNA-MBNL1 binding. To 
date there is no example of gradual dispersion of RNA-MBNL foci by small molecules, and 
these experiments illustrated the difficulty of microscopy as a conclusive assay for validation of 
potential DM1 inhibitors. However, part of the difficulty may have been in the cell model 
chosen. Although primary DM1 cell lines were attractive for their obvious clinical relevance, the 
cells proved cumbersome in practice. As non-immortalized lines, the use of DM1 cells suffered 
from a limit in the number of times the cultures could be passaged (i.e., split for tissue culture 
maintenance). Once the passage limit was reached, the cells underwent morphological changes 
that cast doubt over any subsequent studies. Furthermore, these cells are not as hardy as other 
more commonly used cell lines, and so toxicity was often a barrier to obtaining microscopy 
results. For these reasons, a new model was adopted using transfected HeLa cells (Section 
3.5.2.2). 
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Figure 3.44: Confocal microscopy images taken on a Zeiss LSM510. (a, b) DM1 primary cells show nuclear 
MBNL1 staining and nuclear foci (indicated by arrows); (c) healthy cells show diffuse nuclear MBNL1; (d) DM1 
cells treated with compound 100 μM 1 continue to exhibit MBNL1 as nuclear foci; (e) native fluorescence of 1 
(enhanced for figure) reveals cellular penetration. MBNL1 (green) was visualized by immunofluorescence using a 
mouse-anti-MBNL1 primary antibody and goat-anti-mouse AlexaFluor488 secondary antibody. Actin (red) was 
visualized by AlexaFluor546-phalloidin stain. Scale bar = 10 μm. 
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3.5.2.2 Transfection of Immortalized Cells with GFP-MBNL1 and poly(CUG)  
 In an effort to obtain more consistent and informative results from confocal microscopy 
experiments, a transfected HeLa model was adopted.35 This entailed the insertion of plasmids 
encoding a GFP-MBNL1 fusion protein and a DMPK gene bearing 960 CTG repeats. This 
imparted a measure of control as to the expected levels of MBNL1 and poly(CUG) RNA within 
the cells, and instilled greater confidence in the confocal microscopy images. The use of a GFP 
fusion protein obviated the need to need for antibody-staining for MBNL1; this greatly 
simplified the slide preparation protocol. Meanwhile, poly(CUG) RNA was visualized using a 
fluorescence in situ hybridization (FISH) probe consisting of a Cy3-labeled (CAG)10 DNA 30-
mer. By using the FISH probe, colocalization of the MBNL1 and poly(CUG) foci could be 
observed. Finally, a Hoescht stain was employed to identify cell nuclei. The fact that HeLa 
nuclei comprise the majority of the cell was further justification for switching to a transfection 
model. Image acquisition was also modified, and a three-channel Zeiss LSM700 was employed. 
This instrument is more powerful and more sensitive than the LSM510, allowing clear images 
with an added laser channel. A representative confocal image is shown in Figure 3.45. As shown, 
nuclear foci of both MBNL1 and poly(CUG) are clearly visible, and the merged image displays 
clear colocalization of the foci. With this powerful technique in hand, transfected HeLa were 
treated with hits and derivatives from the DM1 HTS. Disappointly, neither reduction nor 
dispersion of foci was observed for treatment with any of the compounds. 
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Figure 3.45: Confocal microscopy images of HeLa transfected with GFP-MBNL1 and DMPK960. Top left: Hoescht 
stain delineates nuclear boundaries. Top right: GFP enables direct visualization of MBNL1 nuclear foci. Bottom left: 
Cy3-(CAG)10 DNA FISH probe enables visualization of poly(CUG) RNA nuclear foci. Bottom right: Merge image 
displays colocalization of MBNL1 and poly(CUG) foci. Images were taken on a Zeiss LSM700 at 40x zoom using 
405 nm (DNA), 488 nm (MBNL1), and 555 nm (poly(CUG) RNA) channels. 
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3.6 Conclusions and Outlook 
Considerable time and effort went into the development of the HTS for inhibitors of 
DM1. The process was plagued by difficulties with validation efforts and inconsistencies in the 
data. The strong activities of the primary hits from the PC biosensor assay were never fully 
validated by any secondary technique. In fact, the four derivative compounds with the clearest 
inhibitory activity by EMSA also showed the highest toxicity by SRB. Finally, all tested 
compounds failed to show activity in the confocal microscopy DM1 cell models. This project 
lives on in Jessie Peh, whose approach to studying DM1 is focusing on cell studies and DNA 
enzymes, and in the collective efforts of the Zimmerman group, who are continuing to improve 
upon the original designed ligand.  
 
3.7 Materials and Methods 
3.7.1 General 
Buffer solutions were prepared in MilliQ-purified water prior to sterilization by 
autoclaving. All stock solutions were tested for RNase activity with RNase Alert 
(Ambion/Invitrogen). The plasmid pGEX-6P-1-MBNL1-N was donated by Dr. Maurice 
Swanson (U. Florida). Streptavidin-coated 384-well photonic crystal biosensor plates (“SA2” 
plates) were purchased from SRU Biosystems. Primary DM1 human fibroblast cell lines 
GM03132 and GM03987 (both exhibiting disease phenotype with DMPK 3’-UTR’s bearing 
2000 and 500 CTG repeats, respectively) were purchased from the Coriell Institute for Medical 
Research (Camden, NJ). HeLa and Hs888Lu cell lines were purchased from American Type 
Culture Collection (ATTC, Manassas, VA). GFP-MBNL and DMPK960 plasmids were donated 
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by Dr. Thomas Cooper (Baylor College of Medicine). All reagents were obtained from common 
commercial sources and used without further purification. 
3.7.2 RNA Oligomers 
RNA oligonucleotides “CUG4” [5’-G(CUG)2UUCG(CUG)2-3’], “CUG8” [5’-
GG(CUG)8CC-3’], and “CUG12” [5’-GG(CUG)12CC-3’] were purchased from Integrated DNA 
Technologies (IDT, Coralville, IA) and Dharmacon (Thermo Scientific, Lafayette, CO) as 
unlabeled and 5’-modified with biotin or 6-FAM (fluorescein). Oligonucleotides were ordered at 
the standard desalting level of purification and were aliquoted in PBS buffer (pH 7.0) without 
further purification. Before use in an assay, RNA aliquots were refolded as follows: in a PTC-
200 DNA thermal cycler (MJ Research) with a single melting step (95 °C, 2 min) followed by a 
slow refolding step (cooling at 4 °C/min to 4 °C). The program mFold was used to calculate 
melting temperatures (Tm) and predict secondary structure for all nucleic acid oligomers.10 RNA 
constructs were designed such that the calculated ΔΔG˚ between the first and second most stable 
conformations was at least 5 kcal/mol. 
3.7.3 Expression and Purification of MBNL1 
Truncated MBNL1 (MBNL1N) was expressed and purified as reported previously36 
except as indicated. BL21-DE3 E.coli (Invitrogen) was transformed with plasmid pGEX-6P-1-
MBNL1-N by electroporation and induced with 1 mM IPTG. Protein was purified by Ni-NTA 
affinity column. GST column purification was omitted to yield the fusion protein GST-
MBNL1N-His6 (56.3 kDa by low-res MALDI), which was concentrated by centrifugation using 
an Amicon 30K MWCO spin column to 3 mg/L as determined by Bradford assay. 
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3.7.4 Photonic Crystal (PC) Biosensor RNA-Protein Binding Assay 
Streptavidin-coated (SA2) 384-well PC biosensor plates were washed with PBS buffer 
(pH 7.0, 3 × 30 μL, 1 × 15 μL) using a BioTek plate washer and allowed to stabilize (as 
monitored by PWV shift signal) at room temperature prior to use. Kinetic data were measured 
with the biosensor readout instrument (SRU Biosystems BIND Reader) every 30 s for 1 h. 
Biotin-labeled RNA was added (15 μL/well, 10 μM), plates were sealed and allowed to incubate 
overnight at 4 °C. A second wash step (PBS buffer, 3 × 30 μL, 1 × 15 μL) and stabilization at 
room temperature followed. For protein dosing, RNA construct comparison, and sequence 
specificity experiments, protein dilutions were added (15 μL), plates were sealed and allowed to 
incubate at 4 °C for 3 h. Upon stabilization at room temperature, plates were washed (PBS 
buffer, 3 × 30 μL, 1 × 15 μL) and final kinetic data were measured. For measuring inhibitory 
action of free RNA or small molecules, the same procedure was followed, with an additional 
step: after overnight incubation of biotin-labeled RNA and wash step (PBS buffer, 3 × 30 μL), 
dilution stock of free RNA or small molecule was added (15 μL). For aggregation assays, small 
molecule solutions were prepared in buffers containing Tween detergent at concentrations of 
0.01%, 0.05%, and 0.1%. For promiscuity assays, tRNA (at 5-fold base excess) or BSA (0.1 
mg/mL) was added to small molecule solutions to rule out promiscuous RNA- and protein-
binding, respectively. After incubation period of 1h, protein dilution stock was added (15 μL) 
without an intervening wash step. Plates were covered with a thermal seal and allowed to 
incubate at 4 °C for 3 h. Upon stabilization at room temperature, plates were washed (PBS 
buffer, 3 × 30 μL, 1 × 15 μL) and final kinetic data were measured. Compound and protein 
dilutions were transferred to the PC biosensor plate utilizing a Biomek NxP liquid handler 
(Beckman Coulter). 
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3.7.5 Secondary Binding Validation Assays 
3.7.5.1 Surface Plasmon Resonance 
 Surface plasmon resonance (SPR) experiments were performed on a BiaCore 1000 
device according to vendor specifications. To ensure RNase-free conditions, flow channels were 
flushed with a series of cleaning solutions before use, as follows: DEPC-treated water (3x), 100 
mM NaOH (1x), DEPC-treated water (1x), 8M urea (1x), DEPC-treated water (1x), 70% ethanol 
(1x), and DEPC-treated water (1x). For RNA binding experiments, biotinylated CUG8 was 
flown over the active channel of an SA chip until a saturation response was achieved, and test 
ligands were flown over both active and reference (unlabeled) channels. For RNA-protein 
inhibition experiments, GST-MBNL1N-His6 protein was pre-incubated with ligand and then 
flown over both active and reference channels. Sensogram data were analyzed in Excel. 
3.7.5.2 Isothermal Titration Calorimetry 
 Isothermal titration calorimetry (ITC) experiments were performed as previously 
described31 with minor adjustments. Measurements were performed at 25 °C on a MicroCal VP-
ITC calorimeter. Compound solutions (500 µM) were titrated into a sample cell containing 
CUG8 RNA (20 µM) over 20 injections. Initial delay prior to first injection was 10 min to permit 
stabilization of baseline signal. Each injection lasted 24 s followed by a 300 s delay. 
3.7.6 Electrophoretic Mobility Shift Assay (EMSA) 
3.7.6.1 Radiometric EMSA 
CUG12 RNA (5’-GG-(CUG)12-CC-3’) was labeled with [γ-32P]ATP using T4 
polynucleotide kinase (Invitrogen). Radiolabeled RNAs were heated to 95 °C for 2 min and then 
placed on ice for 20 min. RNA samples were diluted to 0.2 nM with buffer containing Tris·HCl 
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(27 mM), NaCl (66 mM), and MgCl2 (6.7 mM), pH 7.5. GST-MBNL1N-His6 proteins were 
serially diluted in buffer containing Tris·HCl (20 mM), NaCl (175 mM), MgCl2 (5 mM), BME 
(1.25 mM), 12.5% glycerol, BSA (2 mg/mL), and heparin (0.1 mg/mL), pH 7.5. Protein and 
RNA solutions were mixed in a 1:1 ratio by volume and incubated at room temperature for 20 
min. The samples were loaded on a 6% polyacrylamide gel (acrylamide/bisacrylamide, 37:1). 
The gel was run at 150 V in 0.5X Tris-borate buffer (pH 8.3) for 1h, vacuum-dried, exposed to 
an autoradiography cassette overnight and visualized on a Typhoon phosphorimager (Molecular 
Dynamics). 
3.7.6.2 Fluorescent EMSA 
 Fluorescein-labeled CUG8 (5’-GG-(CUG)8-CC-3’) RNAs (Dharmacon) were heated to 
95 °C for 2 min and then placed on ice for 20 min. GST-MBNL1N-His6 protein, Fl-CUG8 RNA, 
and ligand solutions were mixed in a 5:5:2 ratio by volume, wrapped in foil, and incubated at 
room temperature for 30 min. Samples were loaded on a 4-20% gradient polyacrylamide gel 
(Bio-Rad). The gel was run at 150 V in 0.5X Tris-borate buffer (pH 8.3) for 1h and visualized on 
a Storm phosphorimager (Molecular Dynamics). 
3.7.7 Fluorescence Titration Assay 
Fluorescence titration experiments were performed as previously described.30 
Fluorescein-labeled RNA oligonucleotides were purchased from IDT and were purified by 
HPLC. Steady-state fluorescence spectra were recorded on a FluoroMax-2 spectrometer 
equipped with a 150 W xenon lamp and modified Czerny–Turner spectrometers in both the 
excitation and emission position utilizing Datamax spectroscopy software. The instrument was 
interfaced with a Neslab RTE-111 temperature controller with a remote sensor. The excitation 
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and emission slits were 4 nm and the excitation wavelength was 485 nm. All fluorescence scans 
were recorded at 20 °C using 1 nm wavelength increments. Samples prepared for fluorescence 
measurements were dissolved in a buffer containing Tris·HCl (20 mM, pH 7.5), NaCl (100 mM), 
MgCl2 (5 mM) and BME (1mM). 
3.7.8 Cell Toxicity 
Toxicities were assessed for immortalized (i.e., HeLa and Hs888Lu) and primary DM1 
(i.e., GM03132 and GM03987) cell lines by Sulforhodamine B (SRB) according to standard 
procedures.37 Cells were seeded at a density of 10,000 cells/well in 96-well plates and were 
subjected to 72 h compound treatment at 37 °C and 5% CO2. Initial compound screens were 
conducted at a single concentration (100 µM). Compounds showing toxicity or insolubility at 
100 µM were taken on to IC50 testing over a 33% dilution concentration set approximating a log 
scale. All singleton concentrations were performed in triplicate and all IC50 tests were performed 
with five technical replicates per concentration. Plates were read on a SpectraMax Plus 
(Molecular Devices) at an absorbance wavelength of 510 nm. 
3.7.9 Fluorescence Laser Confocal Microscopy 
3.7.9.1 Immunohistochemical Staining of Primary Cells 
 Primary DM1 cells (GM03132 and GM03987) were grown on glass cover slips in 6-well 
tissue culture plates at an initial seeding density of 100,000 cells/mL and treated with test 
compounds for 48 h. Cells were fixed with paraformaldehyde and permeabilized with Triton-X. 
MBNL1 was visualized by treatment with mouse-anti-MBNL1 primary antibody (3 h) and goat-
anti-mouse AlexaFluor488 secondary antibody (1 h). Actin was visualized by treatment with 
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AlexaFluor546-phalloidin stain (30 min). Cover slips were mounted on microscopy slides that 
were then imaged on a two-channel Zeiss LSM510 at 488 nm (MBNL1) and 543 nm (actin). 
3.7.9.2 Transfection of GFP-MBNL and poly(CUG) RNA to HeLa Cells 
 Transfected HeLa confocal microscopy was performed as previously described with 
modifications.35 HeLa cells were transfected with DMPK960 and GFP-MBNL plasmids by 
Lipofectamine 2000 (Invitrogen) and grown on glass cover slips in 6-well tissue culture plates at 
an initial seeding density of 100,000 cells/mL. Cells were treated with compound for 48h. Cells 
were fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton-X. Nuclear 
poly(CUG) RNA was visualized by treatment with a Cy3-(CAG)10 FISH probe (3 h). DNA was 
visualized by treatment with Hoescht 33342 stain (30 min). Cover slips were mounted on 
microscopy slides that were then imaged on a three-channel Zeiss LSM700 at 405 nm (DNA), 
488 nm (GFP-MBNL1), and 555 nm (poly(CUG) RNA).  
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CHAPTER 4: DETECTION OF SMALL-MOLECULE BINDING TO 
PROTEIN TARGETS BY AN EXTERNAL CAVITY LASER BIOSENSOR 
 
Portions of the text and figures of this chapter are adapted from the original paper, titled 
“External Cavity Laser Biosensor” (Ge, C.; Lu, M.; George, S.; Flood T.A.; Wagner, C.; Zheng, 
J.; Pokhriyal, A; Siu, C.; Eden, J.G.; Hergenrother, P.J.; Cunningham, B.T. Lab on a Chip. 2013, 
13: 1247-1256) with permission from the publisher.  
 
4.1 Efforts to Improve Upon the Photonic Crystal (PC) Biosensor 
The photonic crystal (PC) biosensor is a powerful optical technology for label-free 
detection of biomolecular interactions in a high-throughput fashion. However, despite the 
advantages of the PC biosensor in terms of throughput, the technology was limited in terms of 
both signal and resolution. As discussed in Chapter 3, PC-based inhibitor assays relied on large 
changes in signal associated with the addition or subtraction of large biomacromolecules (i.e., 
proteins or nucleic acids). Consequently, reliable detection of small-molecule binding could only 
be observed indirectly, by the loss of MBNL1 binding in the DM1 HTS, or by the disruption or 
complexation of protein-protein interaction partners in a previous proof-of-concept study.1 In the 
Cunningham group, variations on the original PC technology were developed in an effort to 
overcome its shortcomings and increase its utility as a biosensor. Figure 4.1 illustrates two 
different approaches to improve the sensor specifications through a material modification of the 
photonic crystal. For the original PC, fabricated low refractive index (RI) material (e.g., 
polycarbonate) is overcoated with high RI material (e.g., TiO2).2-5 The dimensions of the 
diffraction grating combined with the high RI coating produces a photonic crystal that upon 
illumination by incident broadband LED light resonantly reflects a narrow band with a 
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characteristic wavelength value and spectral peak width (Figure 4.1A). In the first modification 
(Figure 4.1B), the TiO2 grating overcoat was modified to include an electron-beam deposition of 
TiO2 nanorods.6 This greatly increased the sensor surface area, permitting modification with test 
molecules (e.g., protein) at higher surface density. Higher target density would allow for 
increased binding interactions, which could be detected by the existing PC biosensor 
instruments. A second modification involved the addition of fluorescent laser dyes to the 
polycarbonate of the sensor grating (Figure 4.1C). This permitted illumination via laser, resulting 
in much narrower spectral width and higher resolution. 
 
Figure 4.1: Schematic of photonic crystal (PC) fabrication and modification efforts to boost signal and resolution. A) 
PC, consisting of a polycarbonate diffraction grating with a TiO2 overcoat, has a characteristic reflectance spectrum 
of given peak wavelength and spectral width. B) Nanorod-coated PC increases the accessible sensor surface for 
biochemical modification, resulting in the potential for signal boost. C) Distributed feedback laser contains lasing 
dyes in the polycarbonate to facilitate laser illumination, resulting in narrower spectral width and concurrently 
increased resolution. 
4.2 External Cavity Laser (ECL) Biosensor 
 The latest incarnation of the PC technology in the Cunningham group is a PC-based 
external cavity laser (ECL) biosensor.7 Briefly, the ECL system consists of a semiconductor 
optical amplifier (SOA) serving as both light source and gain medium with an anti-reflection 
(AR) coating on at least one facet, a collimator for coupling the output of the SOA to the external 
A) B) C) 
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cavity, and an external mode-selection filter, as described in a recent textbook8 and review.9 As 
shown in Figure 4.2, the PC sensor surface acts as one mirror of the laser, and the reflected 
wavelength defines the laser wavelength which is monitored by a spectrometer. Through the 
insertion of a wavelength-selective element into the system (i.e., the PC), an ECL configuration 
permits emission of a single mode with a linewidth that is considerably less than that of a laser 
diode (Figure 4.3 and Table 4.1).9 As with the original PC biosensor, the adsorption of 
biomolecules on the sensor surface alters the peak wavelength value (PWV) of the reflected 
light; in the ECL setup this PWV shift is translated to the laser wavelength. Importantly, a 
narrower spectral linewidth translates to a boost in potential resolution to the point of reliable 
direct detection of small-molecule binding events. The ECL was initially validated as a biosensor 
through the use of a DNA hybridization experiment (Figure 4.4). Briefly, this entailed the 
capture of a polyamine-tagged probe DNA by a glutaraldehyde (GA) surface, followed by 
treatment of a complementary DNA sequence at a range of concentrations to demonstrate dose-
dependence. This validation was encouraging and led to efforts at detecting small-molecule 
binding interactions (Section 4.3). 
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Figure 4.2: Schematic of the external cavity laser (ECL) biosensor system. Light from a semiconductor optical 
amplifier (SOA) is directed via optical fiber to a PC sensor surface, which reflects wavelengths tuned by the 
adsorption of biomolecules on the sensor surface. Light reflected from the PC reenters the SOA and is directed via 
optical fiber to a mirror parallel to the PC. A lasing event occurs, with the PWV and spectral width measured on a 
spectrometer. From Ge, C. et al.7  
 
Figure 4.3: Optical spectra of SOA, PC reflectance, and resulting ECL emission. From Ge, C. et al.7  
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System Peak λ (nm) FWHM (nm) 
LED 900 30-60 
Photonic Crystal (PC) 844 2.1 
HeNe Laser 633 0.01 
PC-based External Cavity Laser 856 0.00003 
 
Table 4.1: Spectral comparisons of common optical systems and photonic crystal platforms. A light-emitting diode 
(LED) produces broadband light (FWHM = 30-60 nm) that effects a resonant reflected narrow band from the 
photonic crystal (PC, FWHM = 2.1 nm). Values from Ge, C. et al7 and Block, I. et al10. 
 
 
Figure 4.4: Validation of the ECL biosensor by detection of DNA hybridization. A) To a glutaraldehyde-modified 
PC sensor plate, 3’-polyamine-tagged probe DNA was bound to the surface by covalent imine formation. Surface 
was rinsed and treated with complementary DNA at a range of concentrations (B) to demonstrate dose-dependent 
binding signal. From Ge, C. et al.7  
 
4.3 Small-Molecule Validation of ECL Biosensor by Known Protein-Ligand Pairs 
4.3.1 Workflow for ECL Validation 
 An efficiency workflow was developed for planning experiments on the ECL biosensor 
(Figure 4.5). Following the selection and acquisition of a protein-ligand pair of interest, the pair 
would first be evaluated on the original PC biosensor at high ligand concentration before 
attempting validation of the ECL biosensor. This workflow enabled the rapid optimization of 
A) B)
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experimental protocols (e.g., protein concentrations) on the PC biosensor in low-volume 384-
well plates. Further, it was necessary to demonstrate a signal increase from a high concentration 
ligand treatment to a protein surface on the PC biosensor before advancing to the ECL. Whereas 
the PC biosensor was housed in a purchased, fully-developed instrument, the ECL biosensor 
setup consisted of assembled components on an optical bench, and considerable calibration was 
required in advance of each measurement. By this workflow, ligands showing binding at high 
concentration by the PC biosensor were advanced to the ECL biosensor, where repeat-results 
were attempted, as well as detection at lower concentrations. 
 
Figure 4.5: Efficiency workflow diagram for ECL small-molecule tests. Upon selection of protein-ligand pairs of 
interest, tests were performed on the PC biosensor to permit optimization of experimental protocols. These included 
establishing test concentrations for the protein and attempting ligand detection at high concentration. Protein-ligand 
pairs were then advanced to the ECL biosensor to attempt repeat-results and detection at lower concentrations. 
 
4.3.2 Previous Validation: Streptavidin and Biotin 
The ultimate goal of the ECL project was the detection of drug or drug-like low 
molecular weight ligands interacting with immobilized protein targets in the context of 
pharmaceutical screening, as modern drug discovery relies largely on high-throughput screening 
(HTS) for the initial identification of lead drug candidates. A conventional demonstration for 
characterizing the ability of a sensor to observe small molecule binding is the detection of biotin 
(MW = 244 Da) by an immobilized capture layer of protein streptavidin (SA, MW = 60 kDa), 
Ligand Selection PC Biosensor Evaluation
ECL Biosensor 
Test
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given the strong binding affinity (Kd = 10-15 M) of this interaction.11 Such a proof-of-concept 
demonstration was performed on the ECL biosensor system, and the dynamic binding curve of 
the biotin-streptavidin interaction is shown in Figure 4.6. Any physical effect in the sample, 
sensor, or detection instrument that can generate a shift of ECL wavelength that is not due to the 
binding of the analyte is considered as a potential error source. The most common sources of 
assay error for label-free biosensors are nonspecific binding and bulk refractive index variability. 
Common-mode error sources such as these can be largely eliminated through the use of a 
negative experimental control by performing the assay within adjacent “active” and “reference” 
microplate wells. Both the active and the reference well are initially functionalized with a high 
density glutaraldehyde layer (GA) that serves as a bi-functional linker to immobilize the capture 
protein to the sensor surface. The capture protein is added to the active well, and allowed to 
covalently bind to the GA surface by imine formation. Excess (unbound) capture protein is 
removed from the well by a washing step with buffer. For both wells, a stable baseline is 
established by filling the well with 30 µL PBS buffer solution, followed by the introduction of 30 
µL small molecule solution (in PBS buffer) into the well. Biotin binding produced a LWS of ~23 
pm on the streptavidin surface, while in the control well no binding signal was observed.  
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Figure 4.6: Demonstration of ECL small-molecule binding of biotin to streptavidin. Lasing wavelength shift (LWS, 
pm) was recorded as a function of time during the exposure of a 250ng/mL (~1 µM) biotin solution to a streptavidin-
activated sensor. From Ge, C. et al.7  
 
4.3.3 Selection of Pharmaceutically Relevant Protein-Ligand Pairs 
Although the demonstration of biotin-streptavidin binding (Section 4.3.2) was important 
as a proof of concept, the interaction in question brings little in the way of pharmaceutical 
relevance. The binding affinity between biotin and streptavidin is on the order of 10-15 M, 
whereas affinities for most screening hits are much weaker.11 Accordingly, the detection of 
weaker-binding protein-ligand pairs of clinical interest was key to a successful validation of the 
ECL as a screening platform for drug discovery. Table 4.2 shows the two proteins and associated 
ligands that were employed for these validation studies. The first targeted protein was estrogen 
receptor α (ER). The estrogen receptors serve a variety of functions in the body and have been 
implicated in a range of diseases including breast cancer, osteoporosis, and atherosclerosis.12 The 
molecular weights of estradiol (272 Da) and ER (63 kDa) are similar to those of biotin and 
streptavidin, but the binding affinity (Kd = 10-10 M) is 105 times lower. Meanwhile, estrone (270 
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Da) binds ER with a lower affinity and was chosen as a comparison ligand. Importantly, these 
interactions have been previously studied in optical biosensor systems, though not in one as 
suitable for high-throughput.13 The second protein was X-linked inhibitor of apoptosis protein 
(XIAP), implicated in cancer for its interactions with caspases.14-15 Synthetic mimics of Smac (a 
protein inhibitor of XIAP) have been designed and represent an interesting series of ligands to 
assess binding of XIAP.16-17 Specifically, the dimeric compound SM-164 binds XIAP with 1000-
fold greater affinity than the monomeric SM-122, and the protected dimer SM-173 shows no 
binding (Table 4.2). The aim with this series was to show a binding profile that matched previous 
non-sensor based studies.16 
 
Ligand Structure Protein Cognate Kd 
estradiol Estrogen Receptor α 700 pM 
estrone Estrogen Receptor α 7 nM 
SM-164 XIAP 560 pM 
 
Table 4.2: Ligands and cognate proteins for small-molecule validation of ECL biosensor technologies. Kd values for 
estradiol and estrone from Rich, R.L. et al.13 Kd values for Smac mimetics from Lu, J. et al.16 
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Ligand Structure Protein Cognate Kd 
SM-122 XIAP 182 nM 
SM-173 XIAP >40 µM 
 
Table 4.2 (continued) : Ligands and cognate proteins for small-molecule validation of ECL biosensor technologies. 
Kd values for estradiol and estrone from Rich, R.L. et al.13 Kd values for Smac mimetics from Lu, J. et al.16 
 
4.3.4 Estrogen Receptor (ER) and Estradiol 
4.3.4.1 PC Biosensor Evaluation 
 Signal levels for ER were assessed on the PC biosensor. Briefly, this entailed the addition 
of ER to a glutaraldehyde-functionalized sensor plate. ER bound to the sensor by covalent imine 
formation by surface amines on the protein. This undirected approach to protein surface 
formation ensures a randomized exposure of the protein binding sites to the ligand solutions. 
Following treatment of ER at a range of concentrations, plates were sealed and incubated at 4 °C 
overnight. Plates were then washed with PBS buffer and returned to room temperature, and 
endpoint measurements were taken. These are summarized in Figure 4.7. Saturation of PWV 
shift signal (~2 nm) was observed at an ER concentration of 625 nM, which was used in 
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subsequent PC and ECL experiments. To evaluate estradiol detection, a range of ligand solutions 
(15 µL at 2x concentration) were added to both GA and ER wells containing 15 µL PBS, and 
kinetic data were measured. Reference-subtracted kinetic data are shown in Figure 4.8. Although 
the signal traces are initially noisy following ligand addition (time t = 10 min), they resolve by 
time t = 20 min to reveal a dose-dependent binding signal. Endpoint data are summarized in 
Figure 4.9. Although the data do not reach saturation as shown, the lack of overlap in the kinetic 
trace for the top concentration (200 µM) relative to all others could suggest an unwanted effect at 
the highest concentration (e.g., precipitation, aggregation). Nevertheless, these results were very 
encouraging and enabled rapid adaptation of the protocol to the ECL sensor. 
 
Figure 4.7: Endpoint data from a rangefinding assay for estrogen receptor (ER) levels on PC biosensor. In a 384-
well glutaraldehyde-functionalized (GA2) plate, 15 µL of ER in PBS (pH 7.0) was added to 15 µL PBS already in 
the well. Plate was thermal sealed and incubated at 4 °C overnight. Plate was then washed with PBS (3× 30 μL, 1× 
15 μL), and final endpoint measurements were taken. Error bars indicate standard deviation (n = 3). ER saturation 
occurs near 625 nM with a ~2nm PWV shift. 
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Figure 4.8: Kinetic data from treatments of estradiol to an ER surface on the PC biosensor. In a 384-well 
glutaraldehyde-functionalized (GA2) plate previously functionalized by treatment with ER (625 nM), 15 µL of 
estradiol at 2x concentration in PBS (pH 7.0, 2% DMSO) was added to 15 µL PBS already in the well. Additions 
occurred at time t = 10 min and data were recorded for an additional 10 min. Ligand solutions were added to bare 
GA wells in the same way. All traces are reference-subtracted and baseline-zeroed. 
 
Figure 4.9: Endpoint data from time t = 20 min for kinetic binding of estradiol to ER (Figure 4.8). 
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4.3.4.2 ECL Biosensor Experiments 
As with the biotin-SA assay, the sensor surface was functionalized with a protein layer of 
ER, resulting in a PWV shift of 2.18 nm (Figure 4.10). Estradiol (50 µL at 2, 25, and 200 µM 
concentration, PBS pH 7.0, 2% DMSO) was then introduced to both a GA and an ER surface 
containing 50 µL PBS. As controls, estrone (200 µM) and PBS (2% DMSO) were added in the 
same way to both GA and ER surfaces. Kinetic data for the individual surface treatments are 
shown in Figure 4.11. Ligand addition occurred at time t ~2 min, and a significant initial shift 
was observed from solution mixing. Signals stabilized by time t = 10 min, and endpoint data are 
shown for the two surfaces in Figure 4.12. PWV shifts on the GA surface are not significantly 
different from the 1% DMSO treatment. Meanwhile, the PWV shifts on the ER surface appear to 
demonstrate binding signal from estradiol that exceeds the bulk shift from DMSO and also 
appears to saturate at 25 µM final concentration. Estrone shows no significant binding signal in 
this experiment. The bulk shift signal seen in all samples came about because ligand solutions 
(containing 2% DMSO) were added to in-well PBS that contained no DMSO. This was corrected 
in subsequent studies so that 2x ligand solutions in 1% DMSO were added to PBS also 
containing 1% DMSO; this eliminated bulk shift artifacts. 
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Figure 4.10: Kinetic data following initial addition of estrogen receptor (ER) to glutaraldehyde (GA) surface on ECL 
biosensor. After ~2 min of stable baseline, 50 µL ER (625 nM) was added to 50 µL PBS. PWV shift in the first 12 
min was ~1.4 nm. Plate was thermal sealed and incubated at 4 °C overnight, then washed with PBS (3× 50 μL) at 
room temperature. PWV shift after overnight incubation was ~2.2 nm.  
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Figure 4.11: Kinetic data from ligand treatments to glutaraldehyde (GA, top graph) and estrogen receptor (ER, 
bottom graph) surfaces on the ECL biosensor. In a 96-well GA2 plate, 50 µL vehicle (2% DMSO), estradiol (at 2x 
concentrations of 2, 25, and 200 µM), and estrone (at 2x concentration of 200 µM) was added to 50 µL PBS (0% 
DMSO) in the well. Ligand addition occurs at time t = 2 min. Large initial shift results from solution mixing and un-
matched DMSO content. Endpoint data were measured at time t = 10 min. 
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Figure 4.12: Endpoint data from ligand treatments to glutaraldehyde (GA) and estrogen receptor (ER) surfaces on 
the ECL biosensor. In a 96-well GA2 plate, 50 µL vehicle (2% DMSO), estradiol (at 2x concentrations of 2, 25, and 
200 µM), and estrone (at 2x concentration of 200 µM) was added to 50 µL PBS (0% DMSO) in the well. A) No 
significant shift in PWV signal was observed above bulk shift from DMSO. B) Estradiol treatments display signal 
over that of vehicle, while estrone shows no significant binding. Error bars indicate the standard deviation of lasing 
wavelength values within individual sensor wells over the final 2 min of data acquisition.  
 
4.3.5 XIAP and Smac Mimetics 
4.3.5.1 PC Biosensor Evaluation 
 PC biosensor experiments with XIAP were performed as with ER (Section 4.3.4). In this 
case, no signal saturation was observed for the XIAP-modification of the GA surface (Figure 
4.13). While it is impossible to conclusively account for this result, it is notable that the 
purification of GST-XIAP was troublesome both in these studies and in previous lab efforts.1 
Therefore protein degradation could account for signals that were lower than expected and failed 
to show saturation. Nevertheless, ligand tests were attempted following overnight treatment of 
XIAP at variable concentrations (Figure 4.14). By itself, the binding of the strong-binding dimer 
SM-164 (purple) looked promising, with potential saturation achieved and maintained for both 
XIAP levels. However, the monomer SM-122 (green) showed a much larger signal that did not 
agree with the known relative affinities for XIAP.16 Meanwhile, the protected dimer negative 
control SM-173 was insoluble in the test buffer (and continued to display insolubility up to 10% 
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DMSO) and was therefore excluded from further studies. Finally, the negative control estradiol 
should not have bound any of the surfaces, yet it displayed signal on the 1 µM XIAP surface. 
Despite these inconclusive results, XIAP and the Smac-mimetics were taken forward to the ECL 
biosensor. 
 
Figure 4.13: Endpoint data from a rangefinding assay for XIAP levels on PC biosensor. In a 384-well 
glutaraldehyde-functionalized (GA2) plate, 15 µL of XIAP in PBS (pH 7.0) was added to 15 µL PBS already in the 
well. Plate was thermal sealed and incubated at 4 °C overnight. Plate was then washed with PBS (3 × 30 μL, 1 × 15 
μL), and final endpoint measurements were taken. Error bars indicate standard deviation (n = 3). Signal saturation 
was never observed in any experiment. 
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Figure 4.14: Reference-subtracted endpoint data for ligand treatments to varying XIAP surfaces on the PC 
biosensor. Following overnight surface modification by 312 nM or 1 µM XIAP, 200 µM solutions (15 µL, PBS 1% 
DMSO) of SM-164, SM-122, and estradiol were added to 15 µL PBS (1% DMSO) and kinetic data were taken for 
10 min. Error bars indicate the standard deviation of peak wavelength values within individual sensor wells over the 
final 2 min of data acquisition. 
4.3.5.2 ECL Biosensor Experiments 
 ECL biosensor experiments with XIAP were performed as with ER (Section 4.3.4). 
Protein modification of the GA surface looked typical, although the signal was relatively low 
given that a higher treatment (1 µM) of XIAP was used (Figure 4.15). Following overnight 
treatment at 1 µM XIAP, 50 µL SM-164 (200 µM in PBS pH 7.0, 1% DMSO) was added to 50 
µL PBS (1% DMSO) at time t = 2 min over both an XIAP and a GA well. Reference-subtracted 
kinetic data are shown in Figure 4.16. Intriguingly, a net positive shift (~6 pm) was observed, 
which was indicative of binding. This is an extremely tenuous result, the shift being barely above 
the baseline signal variation. Further studies could be warranted, using higher-density XIAP 
surfaces and higher concentrations of ligand. However, it should be noted that this protein-ligand 
pair has never previously been evaluated on a biosensor surface, and so any future efforts would 
be purely exploratory. 
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Figure 4.15: Kinetic data following initial addition of XIAP to glutaraldehyde (GA) surface on ECL biosensor. After 
~2 min of stable baseline, 50 µL XIAP (1 µM) was added to 50 µL PBS. PWV shift in the first 12 min was ~1 nm. 
Plate was thermal sealed and incubated at 4 °C overnight, then washed with PBS (3× 50 μL) at room temperature. 
PWV shift after overnight incubation was ~2 nm. 
 
Figure 4.16: Refererence-subtracted kinetic data for treatment of dimeric Smac-mimetic SM-164 against an XIAP 
surface on the ECL biosensor. In a 96-well GA2 plate, 50 µL of SM-164 (200 µM in PBS pH 7.0, 1% DMSO) was 
added to 15 µL PBS (1% DMSO) already in the well at time t = 2 min. This was done over a well treated overnight 
with 1 µM XIAP and a bare GA well, and kinetic data were subtracted.  
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4.4 Conclusions and Outlook 
To date, we have validated the ECL as a biosensor capable of detecting small-molecule 
ligands binding to their corresponding protein target in three separate cases, two of those with 
confidence. Although the technology is still in the early stages of development, it shows great 
promise for future potential screening efforts. As has been discussed previously, label-free 
detection systems offer many advantages in cost, operational simplicity, and biological 
relevance. A platform that could rapidly assess direct binding of small-molecules to a 
macromolecule surface would be revolutionary. In its current state, the ECL system presents an 
interesting combination of power and delicacy. Much care was taken during data acquisition to 
limit thermal perturbations of the laser signal; sudden movements, ventilation drafts, and even 
body heat could have immediately noticeable effects on a kinetic data acquisition. Future efforts 
might be aided by the incorporation of thermal insulation to eliminate this source of noise. 
Currently, efforts are ongoing to further improve the ECL setup; these include parallel readings 
for simultaneous referencing, dual-mode sensors, and incorporation of a programmable 
automated sensor stage.  
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4.5 Materials and Methods 
4.5.1 General 
Buffer solutions were prepared in MilliQ-purified water prior to sterilization by 
autoclaving. Estrogen receptor α ligand-binding domain was generously donated by Dr. Kathy 
Carlson (Katzenellenbogen group). All reagents were obtained from common commercial 
sources and used without further purification. 
4.5.2 Ligand Solutions 
 All small molecule ligands were initially prepared as 10 mM DMSO stock solutions. 
Ligands were further diluted with DMSO to 200x the desired test concentration. Test solutions 
were prepared by adding 200x DMSO stock to PBS buffer (pH 7.0) at a (1:1) ratio to yield a 
100x stock at 50% DMSO; this was then further diluted in PBS at a (1:49) ratio to yield 2x test 
solutions containing 1% DMSO. In sensor experiments all 2x ligand (1% DMSO) solutions were 
added to an equal volume of buffer (containing 1% DMSO) already in the well for a 1x final 
concentration at 1% DMSO. 
4.5.3 Expression and Purification of XIAP 
4.5.3.1 Expression in E.coli 
XIAP was expressed and purified as reported previously1 except as indicated. The cDNA 
encoding human XIAP was provided by Dr. Colin Duckett (University of Michigan) in a pGEX 
vector. BL21-DE3 E.coli (Invitrogen) was transformed with the pGEX-XIAP plasmid by 
electroporation. Culture was grown in a shaker-incubator (250 rpm) at 37 °C to an OD600 ~0.3-
0.4 and induced with 1 mM IPTG at 20 °C for 6 h. Bacteria were harvested by centrifugation at 
6,000 x g, and cell pellets were stored at -20 ºC.  
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4.5.3.2 Purification of GST-XIAP 
Frozen pellets were thawed over ice in 10 mL of binding buffer (PBS + 1 nM DTT). 
Bacteria were lysed by sonication, centrifuged at 35,000 x g, and incubated with 1 mL 
glutathione Sepharose 4B (GE Healthcare) resin slurry for 1 h at 4 °C with constant inversion by 
rotating arm. Resin was washed with an additional 30 mL of PBS + 1 mM DTT, followed by 
elution with 10 mL of elution buffer (PBS + 20 mM glutathione). Protein was dialyzed overnight 
at 4 °C into PBS (pH 7.0) and concentrated using an Amicon 30K MWCO spin concentrator to 
yield GST-XIAP fusion protein (86 kDa). Protein concentration was determined by 
bicinchoninic acid (BCA) assay. 
4.5.4 Photonic Crystal (PC) Biosensor  
Glutaraldehyde-functionalized (GA2) 384-well PC biosensor plates were washed with 
MilliQ water (3 × 50 µL) and PBS buffer (pH 7.0, 3 × 50 μL). PBS buffer (15 µL) was added to 
test wells and peak wavelength value (PWV) signal shift was monitored on a BIND Turbo 
Screener (SRU Biosciences) to establish a stable baseline signal. To determine optimal protein 
treatment concentration, serial dilutions of protein (15 µL) were added to the wells; plates were 
sealed with aluminum thermal seals (Nunc) and stored at 4 °C overnight. Plates were washed 
with PBS buffer (pH 7.0, 3 × 50 μL, 1 × 15 μL) and PWV was measured to determine the 
minimum protein concentration to achieve signal saturation. Ligands were added both to wells 
pre-modified with cognate protein and to bare GA wells. PBS (15 µL) was added and PWV was 
monitored to establish a baseline signal. At time t = 10 min, the BIND instrument was paused, 
ligand solution was added at 2x test concentration, and kinetic measurement was resumed for an 
additional 10 min. Signal traces for bare surface tests were subtracted from traces for the active 
surface tests.  
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4.5.5 External Cavity Laser (ECL) Biosensor 
Glutaraldehyde-functionalized (GA2) 96-well PC biosensor plates were washed with 
MilliQ water (3 × 100 µL) and PBS buffer (pH 7.0, 2 × 100 µL). To a single well, PBS (50 µL) 
was added, and the sensor plate was mounted on the ECL optical stage such that the incident 
light contacted the center of the test well. Guide mirrors were adjusted until a high intensity 
spectral peak was observed on the spectrometer, indicating that the sensor was at parallel and a 
lasing event had been achieved. Kinetic data were recorded as wavelength of ECL emission 
(nm), with readings every 0.5 s. A kinetic baseline was said to be stable if the signal variation 
was <10 pm and no drift was observed. At time t = 2 min, protein solution was added at the 
concentration determined by the PC biosensor rangefinding tests; initial signal increase was 
observed to time t = 10 min, measurement was halted, and plates were sealed with aluminum 
thermal seals (Nunc) and stored at 4 °C overnight. Test wells were washed with PBS (pH 7.0, 3× 
100 µL, 1× 50 µL). Plate was returned to the ECL optical stage at the same location, and mirrors 
were again adjusted to achieve lasing signal. Following 2 min of stable baseline in a kinetic read, 
2x ligand solution (50 µL) was carefully added by micropipette without touching the plate or 
pausing the instrument. Signal was monitored to time t = 10 min. All ligand concentrations were 
tested against both protein-activated and unmodified (GA) surfaces, and kinetic signal traces 
were subtracted.  
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